Mediterranean Multidisciplinary Oncology Forum

Size: px
Start display at page:

Download "Mediterranean Multidisciplinary Oncology Forum"

Transcription

1 Organized by MMOF Mediterranean Multidisciplinary Oncology Forum 1st Congress of the September 2009 Astir Palace Resort Athens, Greece LABEL CONGRESS Accredited with 24 ESMO-MORA points Category 1 F I N A L P R O G R A M M E A N D P R O C E E D I N G S

2

3 auspices-contents Under the auspices of: Ministry of Health and Social Solidarity European Society of Surgical Oncology (ESSO) 1985 HELLENIC SOCIETY OF MEDICAL ONCOLOGY Turkish Oncology Society With the participation of: Mastology Association of Northern and Southern Mediteranean (MANOSMED) contents Welcome Letter...3 Committees Faculty Scientific Programme General Information Acknowledgments Exhibition Plan Congress Proceedings Invited Abstracts Proffered Papers (O1-O30) Poster Presentations (P1-P49) Publications (01-46) Authors Index MMOF

4 AH/BUO/VEC/ /007 VECTIBIX 20mg/ml. 100mg Panitumumab 5 ml. AMGEN... Amgen E ,.: Fax:

5 welcome letter Dear Colleagues, Dear Friends, It is a great honour and pleasure for me, to welcome you, on behalf of the Board of Directors of MMOF, to the 1st Congress of the Mediterranean Multidisciplinary Oncology Forum, held in the beautiful city of Athens, September 2009, at the Astir Palace Resort of Athens. The success of the Hellenic -Turkish ESMO Advanced Courses, held in Istanbul and Athens in 2006 and 2007, lead us to the constitution of a major Oncology Forum with the participation of all Mediterranean countries. We hope to give the opportunity to different schools of Oncology, different civilizations and mentalities to share their knowledge and experience in Oncology. The historical city of Athens, the birthplace of Socrates and Plato, the home of philosophy, democracy and culture is an ideal setting for such an important event and a promising start for something new. We are pleased to prepare and present a comprehensive scientific program with state of the art lectures by world-renowned scientists, plenary symposia, proffered papers and special workshops for Mediterranean young Oncologists. In addition the 2nd BREAST CANCER DAY, a special satellite scientific event, sponsored by ROCHE, in which distinguished speakers from across the globe will provide their expert perspectives on BREAST Cancer, will take place on Friday morning, 11 th of September Wishing and hoping to share with all of you a creative and productive scientific event in Greece, we welcome you in Athens for the 1st MMOF Congress. Dr. Dimitrios I. Bafaloukos President of MMOF Chairman of the Congress 3 MMOF

6 committees Organising Committee (Board of Directors of MMOF) Honorary President: Paris Kosmidis, Chairman/ President: Dimitrios Bafaloukos, Vice President: Haluk Onat, Medical Oncologist, Turkey General Secretary- Membership Committee Chair: Gokhan Demir, Medical Oncologist, Turkey General Secretary- Educational Committee Chair: Helena Linardou, Multidisciplinary Oncology Committee Chair: George Asimakopoulos, Breast Surgeon, Greece Treasurer: Ourania Nicolatou-Galitis, Dentist-Oral Oncology, Greece Meditteranean Executive Officer: Alessandro Testori, Medical Oncologist, Italy Members: Pιnar Saip, Medical Oncologist, Turkey Idris Yϋcel, Medical Oncologist, Turkey Local Organising Committee Chairman: Papadimitriou Christos, Members: Agelaki Sofia, Andreadis Charalambos, Aravantinos Gerasimos, Beroukas Ernestos, Radiation Oncologist, Greece Christopoulou Athina, Kalofonos Charalambos, Kanaloupiti Dimitra, Internist, Greece Karageorgis Pantelis, Radiation Oncologist, Greece Kolokotronis Alexandros, Dentist-Oral Oncology, Greece Mountzios Ioannis, Pantelakos Panagiotis, Radiation Oncologist, Greece Petraki Kalliopi, Pathologist, Greece Rologis Dimitrios, Neurosurgeon, Greece Samantas Epaminondas, Tarampikou Anthi, Oncology Nurse, Greece Tsakiris George, Radiation Oncologist, Greece Tsiotos Grigorios, Surgeon, Greece Zervoudis Stefanos, Breast Surgeon, Greece MMOF 4

7 committees Scientific Committee Chairpersons: Linardou Helena, Demir Gokhan, Medical Oncologist, Turkey Members: Bamias Aristotle, Bavbek Sevil, Medical Oncologist, Turkey Briasoulis Evangelos, Christodoulou Christos, Elad Sharon, Dentist-Oral Oncology, Israel Gaafar Rabab, Medical Oncologist, Egypt Garassino Marina, Medical Oncologist, Italy Gökmen Erhan, Medical Oncologist, Turkey Jezdic Svetlana, Medical Oncologist, ESMO Head Office Karagianni Aikaterini, Dentist-Oral Oncology, Greece Karamouzis Mihalis, Kardamakis Dimitrios, Radiation Oncologist, Greece Kav Sultan, Oncology Nurse, Turkey Klein Baruch, Medical Oncologist, Israel Koutras Aggelos, Mayordomo Jose Ignacio, Medical Oncologist, Spain Metaraku Donika, Medical Oncologist, Malta Molinas Mandel Nil, Medical Oncologist, Turkey Murray Samuel, Molecular Biologist, Greece Οber Ahmet, Radiation Oncologist, Turkey Palla Katerina, Haematologist, Greece Papakostas Pavlos, Papamichael Dimitris, Medical Oncologist, Cyprus Patiraki Elisavet, Oncology Nurse, Greece Ple v stina Stjepko, Medical Oncologist, Croatia Poulakaki Fiorita, Breast Surgeon, Greece Retsas Spyros, Medical Oncologist, UK Rosti Giovanni, Medical Oncologist, Italy Saip Pιnar, Medical Oncologist, Turkey Skarlos Dimosthenis, Yarden Yosef, Molecular Biologist, Israel Abstract Review Committee Linardou Helena, Andreadis Charalambos, Boukovinas John, Droufakou Stravroula, Koutras Aggelos, Murray Samuel, Molecular Biologist, Greece Proffered Papers Award Committee Demir Gokhan, Medical Oncologist, Turkey Dubois Jean-Bernard, Medical Oncologist, France Economopoulos Theophanis, Medical Oncologist, Greece Pavlidis Nikos, Rosti Giovanni, Medical Oncologist, Italy Poster Award Committee Christodoulou Christos, Navrozoglou Iordanis, Gynaecologist, Greece Zervoudis Stefanos, Breast Surgeon, Greece 5 MMOF

8 ÚÔ ˆÚÒÓÙ Ì ÚÔÛÙ ÛÙË ıâú  ÙË Ó ÈÌ. KËÊÈÛ 274, Ã Ï Ó ÚÈ ËÏ , Fax: ñ ª π À º ƒª À π À ƒ : Aranesp 150 microgram ÂÓ ÛÈÌÔ È Ï Ì Û ÚÔÁÂÌÈ- ÛÌ ÓË Û ÚÈÁÁ ÚÔÁÂÌÈÛÌ ÓË Û ÛÎÂ Ù Ô Ó. Aranesp 300 microgram ÂÓ ÛÈÌÔ È Ï Ì Û ÚÔÁÂ- ÌÈÛÌ ÓË Û ÚÈÁÁ ÚÔÁÂÌÈÛÌ ÓË Û ÛÎÂ Ù Ô Ó. Aranesp 500 microgram ÂÓ ÛÈÌÔ È Ï Ì Û ÚÔ- ÁÂÌÈÛÌ ÓË Û ÚÈÁÁ ÚÔÁÂÌÈÛÌ ÓË Û ÛÎÂ Ù Ô Ó. 2. π π π π À : Î ıâ ÚÔÁÂÌÈÛÌ ÓË Û ÚÈÁÁ ÚÔÁÂÌÈÛÌ ÓË Û ÛÎÂ Ù Ô Ó ÂÚÈ ÂÈ 150 microgram ÙË darbepoetin alfa Û 0,3 ml (500 Ìg/ml). Î ıâ ÚÔÁÂÌÈÛÌ ÓË Û ÚÈÁÁ ÚÔÁÂÌÈÛÌ ÓË Û ÛÎÂ Ù Ô Ó ÂÚÈ ÂÈ 300 microgram ÙË darbepoetin alfa Û 0,6 ml (500 Ìg/ml). Î ıâ ÚÔÁÂÌÈÛÌ ÓË Û ÚÈÁÁ ÚÔÁÂÌÈÛÌ ÓË Û ÛÎÂ Ù Ô Ó ÂÚÈ ÂÈ 500 microgram ÙË darbepoetin alfa Û 1 ml (500 Ìg/ml). darbepoetin alfa Ú ÁÂÙ È Ì ÙËÓ ÂÊ ÚÌÔÁ ÁÔÓÈ È Î Ù ÓÔÏÔÁ Û ΠÙÙ Ú ˆÔı ÎË ÎÈÓ ÈÎÔ ÎÚÈÎËÙÔ (CHO-K1). 3. º ƒª Ã π ª ƒº : Ó ÛÈÌÔ È Ï Ì (ÂÓ ÛÈÌÔ) Û ÚÔÁÂÌÈÛÌ ÓË Û ÚÈÁÁ Û ÚÔÁÂÌÈÛÌ ÓË Û ÛÎÂ Ù Ô Ó (SureClick). 4. π π ƒ º ƒπ : 4.1 ÂÚ Â ÙÈÎ ÂÓ Â ÍÂÈ : ıâú  ÙË Û Ì ÙˆÌ ÙÈÎ Ó ÈÌ Ô Û ÂÙ ÂÙ È Ì ÚfiÓÈ ÓÂÊÚÈÎ Ó ÚÎÂÈ (à ) Û ÂÓ ÏÈÎÂ Î È È È ÙÚÈ- ÎÔ ÛıÂÓÂ. ıâú  ÙË Û Ì ÙˆÌ ÙÈÎ Ó ÈÌ Û ÂÓ ÏÈΠÛıÂÓ Ì ΠÚÎ ÓÔ, Ì ÌË-Ì ÂÏÔÁÂ- Ó ΠÎÔ ıâèâ, ÔÈ Ô Ô ÔÈ Ï Ì ÓÔ Ó ËÌÂÈÔıÂÚ Â. 4.2 ÔÛÔÏÔÁ Î È ÙÚfi Ô ÔÚ ÁËÛË : Ó ÚÍË ÙË ıâú  Ì Aranesp Ú ÂÈ Ó Á ÓÂÙ È fi È ÙÚÔ Ì ÂÌ ÂÈÚ ÛÙÈ ÚÔ Ó ÊÂÚı Û ÂÓ Â ÍÂÈ. Ô Aranesp È Ù ıâù È ÙÔÈÌÔ ÚÔ Ú ÛË Û ÚÔÁÂÌÈÛÌ ÓË Û ÚÈÁÁ Û ÚÔÁÂÌÈÛÌ ÓË Û ÛÎÂ Ù Ô Ó. Ô Aranesp Ô ÔÚËÁÂ Ù È Ì ÙËÓ ÚÔÁÂÌÈÛÌ ÓË Û ÛÎÂ Ù Ô Ó (SureClick) Ú ÂÈ Ó ÔÚËÁÂ Ù È ÌfiÓÔ Ô fiúè. ÂÚ Â ÙË Û Ì ÙˆÌ ÙÈÎ Ó ÈÌ ÚÔÎ ÏÔ ÌÂÓË fi ËÌÂÈÔıÂÚ Â Û ÛıÂÓ Ì ΠÚÎ ÓÔ: Ô Aranesp ı Ú ÂÈ Ó ÔÚËÁÂ Ù È Ì Ûˆ ÙË Ô fiúè Ô Ô Û ÛıÂÓ ÌÂ Ó ÈÌ (.. Û ÁÎ - ÓÙÚˆÛË ÈÌÔÛÊ ÈÚ ÓË 10 g/dl (6,2 mmol/l)) ÚÔÎÂÈÌ ÓÔ Ó ÍËıÂ Ë ÈÌÔÛÊ ÈÚ ÓË Û   fi È ÌÂÁ - Ï ÙÂÚ ÙˆÓ 12 g/dl (7,5 mmol/l). Û Ì ÙÒÌ Ù Î È Ù Â ÎfiÏÔ ı ÙË Ó ÈÌ Ì ÔÚÂ Ó ÔÈÎ ÏÔ Ó Ó - ÏÔÁ Ì ÙËÓ ËÏÈÎ, ÙÔ Ê ÏÔ Î È ÙË Û ÓÔÏÈÎ Â È Ú ÓÛË fi ÙËÓ Ûı ÓÂÈ. È ÙÚÈÎ ÍÈÔÏfiÁËÛË ÙË ÎÏÈÓÈ- Î ÔÚÂ Î È ÙË Î Ù ÛÙ ÛË ÙÔ Î ıâ ÛıÂÓ Â Ó È Ú ÙËÙË. fiሠÙË È ÊÔÚÔ Ô ËÛË ÌÂÙ Í ÙˆÓ ÛıÂÓÒÓ, Ì ÔÚÂ Ó Ú ÙËÚËıÔ Ó Û ΠÔÈÔÓ ÛıÂÓ ÂÚÈÛÙ ÛÈ Î ÌÂÌÔÓˆÌ Ó ÙÈÌ ÈÌÔÛÊ ÈÚ ÓË ÌÂÁ Ï ÙÂÚÂ Î È ÌÈÎÚfiÙÂÚ fi Ù Â Èı ÌËÙ Â Â ÈÌÔÛÊ ÈÚ ÓË. È Î Ì ÓÛË ÙË ÈÌÔÛÊ ÈÚ ÓË ı Ú ÂÈ Ó ÓÙÈÌÂÙˆ ÂÙ È ÌÂ È Â ÚËÛË ÙË fiûë, ÔÓÙ fi Ë ÙÔ Â Èı ÌËÙfi  ÚÔ ÛÙfi Ô ÁÈ ÙËÓ ÈÌÔ- ÛÊ ÈÚ ÓË fi 10 g/dl (6,2 mmol/l) ˆ 12 g/dl (7,5 mmol/l).  ÈÌÔÛÊ ÈÚ ÓË Ô È ÙËÚÔ ÓÙ È Óˆ fi 12 g/dl (7,5 mmol/l) ı Ú ÂÈ Ó ÔÊ ÁÔÓÙ È. ËÁ  ÁÈ ÙËÓ Î Ù ÏÏËÏË ÚÔÛ ÚÌÔÁ ÙË fiûë fiù Ó Ú ÙËÚÔ ÓÙ È ÙÈÌ ÈÌÔÛÊ ÈÚ ÓË Ô Í ÂÚÓÔ Ó Ù 12 g/dl (7,5 mmol/l) ÂÚÈÁÚ ÊÔÓÙ È Ú Î Ùˆ. Û ÓÈÛÙÒÌÂÓË Ú ÈÎ fiûë Â Ó È 500 Ìg (6,75 Ìg/kg) Ì ÊÔÚ Î ıâ ÙÚÂÈ Â ÔÌ Â Ì ÔÚÂ Ó ÔÚËÁËı fiûë 2,25 Ìg/kg ÛˆÌ ÙÈÎÔ ÚÔ Ì ÊÔÚ ÙËÓ Â ÔÌ. Ó Ë ÎÏÈÓÈÎ fiîúèûë ÙÔ ÛıÂÓ (Îfi ˆ- ÛË, fiîúèûë ÈÌÔÛÊ ÈÚ ÓË ) Â Ó È Ó ÚÎ ÌÂÙ fi ÂÓÓ Â ÔÌ Â, ÂÚ ÈÙ Úˆ ıâú Â Ì ÔÚÂ Ó ÌËÓ Â Ó È ÔÙÂÏÂÛÌ ÙÈÎ. ıâú  Ì Aranesp ı Ú ÂÈ Ó È Îfi ÙÂÙ È ÂÚ Ô Ù ÛÛÂÚÈ Â ÔÌ Â ÌÂÙ ÙÔ Ù ÏÔ ÙË ËÌÂÈÔıÂÚ Â. ªÂÙ ÙËÓ Â Ù ÍË ÙÔ ıâú  ÙÈÎÔ ÛÙfi Ô ÙÔ Î ıâ ÛıÂÓ, Ë fiûë ı Ú ÂÈ Ó ÌÂÈÒÓÂÙ È Î Ù 25 ˆ 50%, ÒÛÙÂ Ó È ÛÊ Ï ÂÙ È fiùè ÚËÛÈÌÔ ÔÈÂ Ù È Ë ÌËÏfiÙÂÚË ÂÁÎÂ- ÎÚÈÌ ÓË fiûë ÙÔ Aranesp ÚÔÎÂÈÌ ÓÔ Ë ÈÌÔÛÊ ÈÚ ÓË Ó È ÙËÚÂ Ù È ÛÂ Ó Â Â Ô ÛÙÔ Ô Ô Ô ÂÏ Á ÔÓÙ È Ù Û Ì ÙÒÌ Ù ÙË Ó ÈÌ. Ú ÂÈ Ó ÂÍÂÙ ÂÙ È ÙÔ ÂÓ Â fiìâóô Î Ù ÏÏËÏË ÙÈÙÏÔ Ô ËÛË ÙË fiûë ÌÂÙ Í 500 Ìg, 300 Ìg, Î È 150 Ìg. È ÛıÂÓ ı Ú ÂÈ Ó Ú ÎÔÏÔ ıô ÓÙ È ÚÔÛÂÎÙÈÎ Â Ó Ë ÈÌÔ- ÛÊ ÈÚ ÓË ÂÚ Â Ù 12 g/dl (7,5 mmol/l), Ë fiûë ı Ú ÂÈ Ó ÌÂȈı Π٠ÂÚ Ô 25 ˆ 50%. ıâú -  Ì Aranesp ı Ú ÂÈ ÚÔÛˆÚÈÓ Ó È Îfi ÙÂÙ È Ó Ù Â Â ÙË ÈÌÔÛÊ ÈÚ ÓË ÂÚ Ô Ó Ù 13 g/dl (8,1 mmol/l). ıâú  ı Ú ÂÈ Ó Ú ÂÈ Í Ó ÛÂ Â Â Ô ÂÚ Ô 25% Î Ùˆ fi ÙËÓ ÚÔËÁÔ ÌÂÓË fiûë, ÂÊfiÛÔÓ Ù Â Â ÙË ÈÌÔÛÊ ÈÚ ÓË ÌÂȈıÔ Ó Û 12 g/dl (7,5 mmol/l) ÏÈÁfiÙÂÚÔ. Ó Ë ÍËÛË ÙË ÈÌÔÛÊ ÈÚ ÓË Â Ó È ÌÂÁ Ï ÙÂÚË fi 2 g/dl (1,25 mmol/l) Û 4  ÔÌ Â, Ë fiûë ı Ú ÂÈ Ó ÌÂȈı Π٠25 ˆ 50%. 4.3 ÓÙÂÓ Â ÍÂÈ : À ÂÚ ÈÛıËÛ ÛÙËÓ darbepoetin alfa, ÙÔ r-huepo ÛÂ Ô ÔÈÔ ÔÙ fi Ù Î Ô. Ó ÚÎÒ ÂÏÂÁ fiìâóë ÚÙ ÛË. 4.4 È ÈÎ ÚÔÂÈ Ô ÔÈ ÛÂÈ Î È ÚÔÊ Ï ÍÂÈ Î Ù ÙË Ú ÛË: ÂÓÈÎ : ÂÛË ÙÔ Ì ÙÔ ı Ú ÂÈ Ó Ú ÎÔÏÔ ıâ Ù È Û fiïô ÙÔ ÛıÂÓÂ, È È ÙÂÚ Î Ù ÙËÓ Ó ÚÍË ÙË ıâú  Ì Aranesp. Ó Â Ó È ÛÎÔÏÔ Ó ÂÏÂÁ ıâ Ë ÂÛË ÙÔ Ì ÙÔ Ì ÙËÓ ÂÊ ÚÌÔÁ ÙˆÓ Î Ù ÏÏËÏˆÓ Ì ÙÚˆÓ, Ë ÈÌÔÛÊ ÈÚ ÓË ı Ú ÂÈ Ó ÂÏ ÙÙÒÓÂÙ È Ì ÙË Ì ˆÛË Û ÁÎÚ ÙËÛË ÙË fiûë ÙÔ Aranesp ( Ï Â Ú ÁÚ ÊÔ 4.2). ÚÔÎÂÈÌ ÓÔ Ó È ÛÊ ÏÈÛÙÂ Ë ÔÙÂÏÂÛÌ ÙÈÎ ÂÚ ıúô Ô ËÛË, ÚÈÓ Î È Î Ù ÙË È ÚÎÂÈ ÙË ıâú Â, ı Ú ÂÈ Ó ÍÈÔÏÔÁÂ Ù È Ë Î Ù ÛÙ ÛË ÙÔ ÛÈ ÚÔ ÁÈ fiïô ÙÔ ÛıÂ- ÓÂ Û Ì ÏËÚˆÌ ÙÈÎ Â ıâú  ÌÂ Û ËÚÔ Ì ÔÚÂ Ó Â Ó È Ú ÙËÙË. ÌË fiîúèûë ÛÙË ıâú  Ì Aranesp ı Ú ÂÈ Ó ÔÙÂÏ ÛÂÈ ÙÈÔ ÈÂÚ ÓËÛË ÙˆÓ ÈÙÈÔÏÔÁÈÎÒÓ Ú ÁfiÓÙˆÓ. È Ó ÚÎÂÈ ÙÔ ÛÈ ÚÔ, ÙÔ ÊÔÏÈÎÔ ÔÍ Ô ÙË µèù Ì ÓË B12 ÌÂÈÒÓÔ Ó ÙËÓ ÔÙÂÏÂÛÌ ÙÈÎfiÙËÙ ÙˆÓ Ú ÁfiÓÙˆÓ È - ÁÂÚÛË ÙË ÂÚ ıúô Ô ËÛË Î È Â ÔÌ Óˆ ı Ú ÂÈ Ó ÔÎ ı ÛÙ ÓÙ È. È ÂÓ È ÌÂÛ ÏÔÈÌÒÍÂÈ, Ù ÊÏÂÁ- ÌÔÓÒ Ë ÙÚ Ì ÙÈÎ Â ÂÈÛfi È, Ë Ï Óı ÓÔ Û ÒÏÂÈ Ì ÙÔ, Ë ÈÌfiÏ ÛË, Ë ÛÔ Ú ÙÔÍ ÎˆÛË ÚÁÈÏ Ô, ÔÈ ÔΠÌÂÓ ÈÌ ÙÔÏÔÁÈÎ Ûı ÓÂÈÂ Ë ÓˆÛË ÙÔ Ì ÂÏÔ ÙˆÓ ÔÛÙÒÓ ÂÓ ÂÙ È Â ÛË Ó ÌÂÈÒÛÔ Ó ÙËÓ ÂÚ ıúô ÔÈËÙÈÎ fiîúèûë. ÚÈıÌfi ÙˆÓ ÈÎÙ ÔÂÚ ıúôî ÙÙ ÚˆÓ ı Ú ÂÈ Ó ıâˆúâ Ù È Ì ÚÔ ÙË ÍÈÔ- ÏfiÁËÛË. ÙËÓ ÂÚ ÙˆÛË Ô ÔÈ Ù ÈÎ ÈÙ Â ÌË ÓÙ fiîúèûë Ô Ó ÔÎÏÂÈÛÙÂ, Î È Ô ÛıÂÓ ÂÌÊ Ó - ÂÈ ÈÎÙ ÔÂÚ ıúôî ÙÙ ÚÔ ÂÓ, ı Ú ÂÈ Ó ÂÍÂÙ ÂÙ È Ë ÂÚ ÙˆÛË ÂÏ Á Ô ÙÔ Ì ÂÏÔ ÙˆÓ ÔÛÙÒÓ. Ó Ë ÂÈÎfiÓ ÙÔ Ì ÂÏÔ ÙˆÓ ÔÛÙÒÓ Â Ó È Û Ì Ù Ì ÌÈÁ ÂÚ ıúôî ÙÙ ÚÈÎ Ï Û (PRCA), ı Ú ÂÈ Ó ÈÂ- ÓÂÚÁÂ Ù È ÏÂÁ Ô ÁÈ ÓÙÈ-ÂÚ ıúô ÔÈËÙÈÎ ÓÙÈÛÒÌ Ù. ÌÈÁ ÂÚ ıúôî ÙÙ ÚÈÎ Ï Û ÏfiÁˆ Ó Ù ÍË ÂÍÔ ÂÙÂÚˆÙÈÎÒÓ ÓÙÈ-ÂÚ ıúô ÔÈËÙÈÎÒÓ ÓÙÈÛˆÌ ÙˆÓ ÂÈ Ó ÊÂÚıÂ Ó Û ÂÙ ÂÙ È Ì ÙÈ Ó Û Ó ÛÌ Ó ÂÚ ıúô ÔÈËÙÈÎ ÚˆÙ ÓÂ, Û Ì ÂÚÈÏ Ì ÓÔÌ ÓË ÙË darbepoetin alfa. Ùfi ÂÈ Î Ú ˆ Ó ÊÂÚı Û ÛıÂÓ Ì ÃÚfiÓÈ ÂÊÚÈÎ Ó ÚÎÂÈ (à ), ÔÈ Ô Ô ÔÈ Ï Ì Ó Ó ÙË ıâú Â Ô ÔÚ ˆ. Œ ÂÈ Î Ù ÂÈ- ıâ, fiùè Ù ÓÙÈÛÒÌ Ù Ù Ú ÎÙËÚ ÔÓÙ È fi È ÛÙ ÚÔ ÌÂÓË ÓÙ Ú ÛË Ì fiïâ ÙÈ ÂÚ ıúô ÔÈËÙÈÎ ÚˆÙ ÓÂ Î È ÛıÂÓ ÌÂ Ô Â È Â ÈˆÌ ÓË ÚÔ Û ÂÍÔ ÂÙÂÚˆÙÈÎÒÓ ÓÙÈÛˆÌ ÙˆÓ Û ÂÚ ıúô- ÔÈËÙ ÓË, ÂÓ Ú ÂÈ Ó ÌÂÙ Ù ÛÛÔÓÙ È Û darbepoetin alfa ( Ï. Ú ÁÚ ÊÔ 4.8). ÂÓÂÚÁ Ë ÙÔ ıâè Ù Ó ÎÚÈÙ ÚÈÔ ÔÎÏÂÈÛÌÔ Û fiïâ ÙÈ ÌÂÏ Ù ÙÔ Aranesp Î È, Û Ó Ò, ÂÓ Ú Ô Ó È ı ÛÈÌ Â ÔÌ Ó fi ÛıÂÓ ÌÂ Ï Ë ÙË Ë ÙÈÎ ÏÂÈÙÔ ÚÁ. ÂÈ ÙÔ Ú ıâˆúâ Ù È fiùè ÔÙÂÏ ÙËÓ Î ÚÈ Ô fi Ô- ÔÏ ÙÔ Aranesp Î È ÙÔ r-huepo, ÙÔ Aranesp ı Ú ÂÈ Ó ÚËÛÈÌÔ ÔÈÂ Ù È Ì ÚÔÛÔ Û ÛıÂÓ ÌÂ Ë ÙÔ ıâè. Ô Aranesp ı Ú ÂÈ Â ÛË Ó ÚËÛÈÌÔ ÔÈÂ Ù È Ì ÚÔÛÔ Û ÂΠÓÔ ÙÔ ÛıÂÓÂ Ô Û Ô Ó fi Ú ÓÔÎ ÙÙ ÚÈÎ Ó ÈÌ Â ÈÏË. ÂÛÊ ÏÌ ÓË Ú ÛË ÙÔ Aranesp fi ÁÈ ÙÔÌ Ì ÔÚÂ Ó Ô ËÁ ÛÂÈ Û ÂÚ ÔÏÈÎ ÍËÛË ÙÔ fiáîô ÙˆÓ ÌÌÔÚÊˆÓ Û ÛÙ ÙÈÎÒÓ ÙÔ Ì ÙÔ, Î Ù ÛÙ ÛË Ô Ûˆ Û ÂÙ ÂÙ È Ì ÂÈÏËÙÈÎ ÁÈ ÙË ˆ Â È ÏÔÎ fi ÙÔ Î Ú È ÁÁÂÈ Îfi Û ÛÙËÌ. Ô Î Ï ÌÌ ÙË ÂÏfiÓ ÙË ÚÔÁÂÌÈÛÌ ÓË Û ÛÎÂ Ù Ô Ó ÂÚÈ ÂÈ ÍËÚfi Ê ÛÈÎfi ÂÏ ÛÙÈÎfi ( Ó Ú ÁˆÁÔ ÙÔ Ï ÙÂÍ), ÙÔ Ô Ô Ô Ì ÔÚÂ Ó ÚÔÎ Ï ÛÂÈ ÏÏÂÚÁÈÎ ÓÙÈ Ú ÛÂÈ.  ÛıÂÓ Ì ÚfiÓÈ ÓÂÊÚÈÎ Ó ÚÎÂÈ, Ë Û ÁÎ ÓÙÚˆÛË ÙË ÈÌÔÛÊ ÈÚ ÓË Û ÓÙ ÚËÛË ÂÓ ı Ú ÂÈ Ó ÂÚ ÓÂÈ ÙÔ ÓÒÙÂÚÔ fiúèô ÙË Û ÁÎ ÓÙÚˆÛË ÙË ÈÌÔ- ÛÊ ÈÚ ÓË -ÛÙfi Ô Ô Û ÛÙ ÓÂÙ È ÛÙËÓ Ú ÁÚ ÊÔ 4.2.  ÎÏÈÓÈÎ ÌÂÏ ÙÂ, Ú ÙËÚ ıëîâ ÍËÌ ÓÔ Î Ó- ÓÔ ı Ó ÙÔ, ÛÔ ÚÒÓ Î Ú È ÁÁÂÈ ÎÒÓ Â ÂÈÛÔ ˆÓ Î È ıúfiì ˆÛË ÁÁÂÈ Î ÚÔÛ Ï ÛË fiù Ó ÔÈ Ú - ÁÔÓÙÂ È ÁÂÚÛË ÙË ÂÚ ıúô Ô ËÛË (ESAs) ÔÚËÁ ıëî Ó ÁÈ ÙËÓ Â Ù ÍË ÈÌÔÛÊ ÈÚ ÓË ËÏfiÙÂÚË ÙˆÓ 12 g/dl (7,5 mmol/l). ÏÂÁ fiìâóâ ÎÏÈÓÈÎ ÌÂÏ Ù ÂÓ ÂÈÍ Ó ÛËÌ ÓÙÈÎ ÔÊ ÏË Ô È fiìâó ÛÙË ÔÚ ÁË- ÛË ÂÚ ıúô ÔÈËÙÈÓÒÓ fiù Ó Ë Û ÁÎ ÓÙÚˆÛË ÙË ÈÌÔÛÊ ÈÚ ÓË Í ÓÂÙ È Óˆ fi ÙÔ Â Â Ô Ô ÈÙÂ Ù È ÁÈ ÙÔÓ ÏÂÁ Ô ÙˆÓ Û Ì ÙˆÌ ÙˆÓ ÙË Ó ÈÌ Î È ÙËÓ ÔÊ Á ÙˆÓ ÌÂÙ ÁÁ ÛÂˆÓ Ì ÙÔ. Ô Aranesp ı Ú ÂÈ Ó ÚËÛÈÌÔ ÔÈÂ Ù È Ì ÚÔÛÔ Û ÛıÂÓ Ì  ÈÏË. Œ Ô Ó Ó ÊÂÚıÂ Û ÛÌÔ Û ÛıÂÓÂ Ô Ï Ì ÓÔ Ó Aranesp. ÛıÂÓ Ì ΠÚÎ ÓÔ: Ú ÛË ÛÙËÓ ÍËÛË ÙÔ fiáîô : È ÂÚ ıúô ÔÈËÙ ÓÂ Â Ó È ÍË- ÙÈÎÔ Ú ÁÔÓÙÂ Ô Î Ú ˆ ÈÂÁ ÚÔ Ó ÙËÓ Ú ÁˆÁ ÂÚ ıúôî ÙÙ ÚˆÓ. È Ô Ô Â ÙË ÂÚ ıúô ÔÈËÙ - ÓË Ì ÔÚÂ Ó ÂÎÊÚ ÔÓÙ È ÛÙËÓ Â ÈÊ ÓÂÈ ÔÈÎ ÏˆÓ Î ÚÎÈÓÈÎÒÓ Î ÙÙ ÚˆÓ. Ÿ ˆ Ì fiïô ÙÔ ÍËÙÈÎÔ Ú ÁÔÓÙÂ, Ú ÂÈ Ë ÓËÛ fiùè ÔÈ ÂÚ ıúô ÔÈËÙ Ó ı Ì ÔÚÔ Û Ó Ó ÈÂÁ ÚÔ Ó ÙËÓ ÍËÛË fiáîˆó.  ÚÎÂÙ ÂÏÂÁ fiìâóâ ÌÂÏ ÙÂ, ÔÈ ÂÚ ıúô ÔÈËÙ Ó ÂÓ Ê ÓËÎÂ Ó ÂÏÙÈÒÓÔ Ó ÙË Û ÓÔÏÈÎ Â È ˆÛË Ó ÌÂÈÒÓÔ Ó ÙÔÓ Î Ó ÓÔ ÂÍ ÏÈÍË ÙÔ fiáîô Û ÛıÂÓ ÌÂ Ó ÈÌ Û ÂÙÈ fiìâóë Ì ΠÚÎ ÓÔ.  ÂÏÂÁ fiìâóâ ÎÏÈÓÈÎ ÌÂÏ ÙÂ, Ë Ú ÛË ÙÔ Aranesp Î È ÏÏˆÓ Ú ÁfiÓÙˆÓ È ÁÂÚÛË ÙË ÂÚ ıúô Ô ËÛË (ESAs) Î Ù - ÂÈÍÂ: ñ Ì ˆÛË ÙÔ ÚfiÓÔ Ì ÚÈ ÙËÓ ÂÍ ÏÈÍË ÙÔ fiáîô Û ÛıÂÓ Ì ÚÔ ˆÚËÌ ÓÔ Î ÚÎ ÓÔ ÙË ÎÂÊ - Ï Î È ÙÔ ÙÚ ÏÔ, ÔÈ Ô Ô ÔÈ Ï Ì Ó Ó ÎÙÈÓÔıÂÚ Â, fiù Ó ÔÚËÁ ıëî Ó ÁÈ ÙËÓ Â Ù ÍË ÈÌÔÛÊ ÈÚ - ÓË ÌÂÁ Ï ÙÂÚË ÙˆÓ 14 g/dl (8,7 mmol/l)ø ÔÈ Ú ÁÔÓÙÂ È ÁÂÚÛË ÙË ÂÚ ıúô Ô ËÛË ÂÓ ÂÓ Â ÎÓ ÓÙ È ÁÈ Ú ÛË Û Ùfi ÙÔÓ ÏËı ÛÌfi ÛıÂÓÒÓ. ñ Ì ˆÛË ÙË ÔÏÈÎ Â È ˆÛË Î È ÍËÛË ÙˆÓ Ô ÂÈ fiìâóˆó ÛÙËÓ ÂÍ ÏÈÍË ÙË ÓfiÛÔ ı Ó ÙˆÓ ÛÙÔ 4 Ì Ó Û ÛıÂÓ Ì ÌÂÙ ÛÙ ÙÈÎfi Î ÚÎ ÓÔ ÙÔ Ì ÛÙÔ ÔÈ Ô Ô ÔÈ Ï Ì ÓÔ Ó ËÌÂÈÔıÂÚ Â, fiù Ó ÔÚËÁ ıëî Ó ÁÈ ÙËÓ Â Ù ÍË ÈÌÔÛÊ ÈÚ ÓË g/dl (7,5 8,7 mmol/l). ñ ÍËÛË ÙÔ ÎÈÓ ÓÔ ı Ó ÙÔ fiù Ó ÔÚËÁ ıëî Ó ÁÈ ÙËÓ Â Ù ÍË ÈÌÔÛÊ ÈÚ ÓË 12 g/dl (7,5 mmol/l) Û ÛıÂÓ Ì ÂÓÂÚÁ Î ÎÔ ıâè Ô ÂÓ Ï Ì Ó Ó Ô Ù ËÌÂÈÔıÂÚ Â Ô Ù ÎÙÈÓÔıÂÚ Â Ø ÔÈ Ú ÁÔÓÙÂ È ÁÂÚÛË ÙË ÂÚ ıúô Ô ËÛË ÂÓ ÂÓ Â ÎÓ ÓÙ È ÁÈ Ú ÛË Û Ùfi ÙÔÓ ÏËı ÛÌfi ÛıÂÓÒÓ. Ó fi ÂÈ ÙˆÓ Óˆ- Ù Úˆ, Û ÔÚÈÛÌ Ó ÎÏÈÓÈÎ ÂÚÈÛÙ ÛÂÈ Ë ÚÔÙÈÌÔ ÌÂÓË ıâú  ÁÈ ÙË È Â ÚÈÛË ÙË Ó ÈÌ Û ÛıÂ- Ó Ì ΠÚÎ ÓÔ ı Ú ÂÈ Ó Â Ó È Ë ÌÂÙ ÁÁÈÛË Ì ÙÔ. fiê ÛË ÁÈ ÙË ÔÚ ÁËÛË Ó -Û Ó ÛÌ ÓˆÓ ÂÚ ıúô ÔÈËÙÈÓÒÓ, Ë Ô Ô ı Ú ÂÈ Ó Ú ÁÌ ÙÔ ÔÈÂ Ù È Ì ÙË Û ÌÌÂÙÔ ÙÔ Û ÁÎÂÎÚÈÌ ÓÔ ÛıÂÓ, ı Ú - ÂÈ Ó Û ÂÙ È ÛÂ Ì ÍÈÔÏfiÁËÛË ÔÊ ÏÔ - ÎÈÓ ÓÔ, Ë Ô Ô ı Ú ÂÈ Ó Ï Ì ÓÂÈ fi Ë ÙÔ Û ÁÎÂÎÚÈ- Ì ÓÔ ÎÏÈÓÈÎfi Ï ÛÈÔ. ÙÔ Ú ÁÔÓÙÂ Ô ı Ú ÂÈ Ó Ï Ì ÓÔÓÙ È fi Ë Î Ù ÙËÓ ÍÈÔÏfiÁËÛË Ù ı Ú ÂÈ Ó ÂÚÈÏ Ì ÓÔÓÙ È Ô Ù Ô ÙÔ fiáîô Î È ÙÔ ÛÙ Èfi ÙÔ, Ô ıìfi ÙË Ó ÈÌ, ÙÔ ÚÔÛ fiîèìô ˆ, ÙÔ ÂÚÈ ÏÏÔÓ ÛÙÔ Ô Ô Ô Ô ÛıÂÓ Ï Ì ÓÂÈ ıâú Â Î È Ë ÚÔÙ ÌËÛË ÙÔ ÛıÂÓ.  ÛıÂÓ ÌÂ Û Ì - Á fiáîô ÏÂÌÊÔ ÂÚ Ï ÛÙÈÎ Î ÎÔ ıâèâ, Ó Ë ÙÈÌ ÙË ÈÌÔÛÊ ÈÚ ÓË ÂÚ Â Ù 12g/dl (7,5 mmol/l), Ë ÚÔÛ ÚÌÔÁ ÙË ÔÛÔÏÔÁ Ô ÂÚÈÁÚ ÊÂÙ È ÛÙËÓ Ú ÁÚ ÊÔ 4.2 ı Ú ÂÈ Ó ÎÔÏÔ ıâ Ù È ÈÛÙ, ÚÔ- ÎÂÈÌ ÓÔ Ó ÂÏ ÈÛÙÔ ÔÈËıÂ Ô Èı Ófi Î Ó ÓÔ ıúôì ÔÂÌ ÔÏÈÎÒÓ Â ÂÈÛÔ ˆÓ. ÚÈıÌfi ÙˆÓ ÈÌÔ ÂÙ Ï ˆÓ Î È Ù Â Â ÙË ÈÌÔÛÊ ÈÚ ÓË ı Ú ÂÈ Â ÛË Ó Ú ÎÔÏÔ ıô ÓÙ È Ó Ù ÎÙ ÚÔÓÈÎ È ÛÙ Ì Ù. 4.5 ÏÏËÏÂ È Ú ÛÂÈ Ì ÏÏ Ê ÚÌ Î ÙÈÎ ÚÔ fióù Î È ÏÏ ÌÔÚÊ ÏÏËÏÂ Ú ÛË : Ì ÚÈ ÛÙÈÁÌ ÎÏÈ- ÓÈÎ ÔÙÂÏ ÛÌ Ù ÂÓ Ô ÂÈÎÓ Ô Ó Ô ÔÈ ÔÙ ÏÏËÏÂ Ú ÛË ÙÔ Aranesp Ì ÏÏÂ Ô Û Â. øûùfiûô, Ú ÂÈ ÙÔ ÂÓ Â fiìâóô ÏÏËÏÂ Ú ÛË ÌÂ Ê ÚÌ Î Ù Ô Ô ÂÛÌ ÔÓÙ È ÈÛ Ú Ì ٠ÂÚ ıú ÈÌÔÛÊ ÚÈ,.. cyclosporin, tacrolimus. Ó Ë darbepoetin alfa ÔÚËÁËıÂ Ú ÏÏËÏ Ì ΠÔÈÔ fi Ù Ù Ê ÚÌ Î, ı Ú ÂÈ Ó Ú ÎÔÏÔ ıô ÓÙ È Ù Â Â ÙÒÓ ÙˆÓ Ê ÚÌ ÎˆÓ ÛÙÔ Ì Î È Ó Ú ıì ÂÙ È Ë ÔÛÔÏÔÁ, Î ıò Í ÓÂÙ È Ë ÈÌÔÛÊ Ú ÓË. 4.6 ËÛË Î È Á ÏÔ : ÂÓ È Ù ıâóù È ÎÏÈÓÈÎ Â ÔÌ Ó Û ÂÙÈÎ Ì ÎıÂÛË Î Ù ÙËÓ ÂÁÎ ÌÔÛ ÓË ÛÙÔ Aranesp. ªÂÏ Ù ÛÂ Ò ÂÓ Î Ù ÂÈÍ Ó ÌÂÛ  ÈÎ Ó ÓÂ Â È ÙÒÛÂÈ ÛÙËÓ ÂÁÎ ÌÔ- Û ÓË, ÛÙËÓ Ó Ù ÍË ÙÔ ÂÌ Ú Ô, ÛÙÔÓ ÙÔÎÂÙfi ÛÙË ÌÂÙ ÁÂÓÓËÙÈÎ Ó Ù ÍË. ÔÚ ÁËÛË Û ÁÎ Â Á Ó - ÎÂ Ú ÂÈ Ó Ú ÁÌ ÙÔ ÔÈÂ Ù È ÌÂ È È ÙÂÚË ÚÔÛÔ. ıò ÂÓ Ú ÂÈ ÎÏÈÓÈÎ ÂÌ ÂÈÚ Ì ıëï Ô Û Á Ó ÎÂ, ÙÔ Aranesp ÂÓ ı Ú ÂÈ Ó ÔÚËÁÂ Ù È Û Á Ó ÎÂ Ô ıëï Ô Ó. ŸÙ Ó Ë ıâú  Ì Aranesp ÂÓ Â ÎÓ Ù È fiï Ù, ÔÈ Á Ó ÎÂ Ú ÂÈ Ó ÛÙ Ì Ù ÛÔ Ó ÙÔ ıëï ÛÌfi. 4.7 È Ú ÛÂÈ ÛÙËÓ ÈÎ ÓfiÙËÙ Ô - ÁËÛË Î È ÂÈÚÈÛÌÔ ÌË ÓÒÓ: ÂÓ ÂÈ Ú ÙËÚËıÂ Î Ì Â Ú ÛË ÙÔ Aranesp ÛÙËÓ ÈÎ ÓfiÙËÙ Ô ÁËÛË Î È ÂÈÚÈÛÌÔ ÌË ÓÒÓ. 4.8 Ó Èı ÌËÙ ÂÓ ÚÁÂÈ : ÂÓÈÎ : Œ Ô Ó Á ÓÂÈ Ó ÊÔÚ ÛÔ ÚÒÓ ÏÏÂÚÁÈÎÒÓ ÓÙÈ Ú ÛÂˆÓ Ô Û ÂÙ ÔÓÙ È Ì darbepoetin alfa, Û Ì ÂÚÈÏ Ì ÓÔÌ ÓˆÓ Ó Ê Ï ÎÙÈÎ ÓÙ Ú ÛË, ÁÁÂÈÔ- ÔÈ Ì ÙÔ, Û ÓÔÈ, ÂÚÌ ÙÈÎÔ ÂÍ Óı Ì ÙÔ Î È ÎÓ ˆÛË. Ì ÂÈÚ fi ÎÏÈÓÈÎ ÌÂÏ Ù : ÛıÂÓ Ì ΠÚÎ ÓÔ: È Ó Èı ÌËÙ ÂÓ ÚÁÂÈ ÚÔÛ ÈÔÚ ÛÙËÎ Ó ÛÂÈ Û ÁÎÂÓÙÚˆÙÈÎÒÓ Â ÔÌ ÓˆÓ fi  ٠٠ÈÔ- ÔÈËÌ ÓÂ, È Ï Ù ÊÏ, ÂÏÂÁ fiìâóâ Ì ÂÈÎÔÓÈÎfi Ê ÚÌ ÎÔ ÌÂÏ Ù Ì Aranesp ÛÙÈ Ô Ô Â Û ÌÌÂÙÂ Ó Û ÓÔÏÈÎ 2112 ÛıÂÓ (Aranesp 1200, ÂÈÎÔÓÈÎfi Ê ÚÌ ÎÔ 912). ÙÈ ÎÏÈÓÈÎ ÌÂÏ ÙÂ Û Ì ÂÚÈÏ ÊıËÎ Ó ÛıÂÓ ÌÂ Û Ì Á fiáîô (.. Î ÚÎ ÓÔ Ó ÌÔÓ, Ì ÛÙÔ, Ô ÂÓÙ ÚÔ, ˆÔıËÎÒÓ) Î È ÏÂÌÊÔÂÈ-  ΠÎÔ ıâèâ (.. Ï ÌʈÌ, ÔÏÏ Ïfi Ì ÏˆÌ ). Û ÓfiÙËÙ ÂÌÊ ÓÈÛË Ó Èı ÌËÙˆÓ ÂÓÂÚÁÂÈÒÓ, ÔÈ Ô Ô Â ıâˆú ıëî Ó fiùè Û ÂÙ ÔÓÙ È Ì ÙËÓ ıâú  Aranesp Î Ù ÙÈ ÂÏÂÁ fiìâóâ ÎÏÈÓÈÎ ÌÂÏ ÙÂ Â Ó È: È Ù Ú ÙÔ ÚÌ ÙÔ Î È ÙÔ Ô fiúèô ÈÛÙÔ : Ó ( 1/100 ˆ <1/10) Í ÓıËÌ / Ú ıëì. ÁÁÂÈ Î È Ù Ú : Ó ( 1/100 ˆ <1/10) ÚÔÌ ÔÂÌ ÔÏÈÎ Â ÂÈÛfi È, Û Ì ÂÚÈÏ Ì ÓÔÌ ÓË Ó ÌÔÓÈÎ ÂÌ ÔÏ. ÂÓÈÎ È Ù Ú Î È Î Ù ÛÙ ÛÂÈ ÙË Ô Ô ÔÚ ÁËÛË : ÔÏ Û Ó ( 1/10) Ë- Ì. Ó ( 1/100 ˆ <1/10) ÕÏÁÔ ÙË ı ÛË ÓÂÛË. Ì ÂÈÚ ÌÂÙ ÙËÓ Î ÎÏÔÊÔÚ ÛÙËÓ ÁÔÚ : È ÎfiÏÔ ıâ Ó Èı ÌËÙ ÂÓ ÚÁÂÈÂ Ô Ó È ÈÛÙˆı Π٠ÙË Ú ÛË ÙÔ Aranesp ÌÂÙ ÙËÓ Î ÎÏÔÊÔÚ ÙÔ ÛÙËÓ ÁÔÚ : ñ ÌÈÁ Ú ıúôî ÙÙ ÚÈÎ Ï Û.  ÌÂÌÔÓˆÌ Ó ÂÚÈ ÙÒÛÂÈ, ÂÈ Ó ÊÂÚı ÌÈÁ ÂÚ ıúôî ÙÙ ÚÈÎ Ï Û (PRCA) È ÌÂÛÔÏ Ô ÌÂÓË fi ÂÍÔ ÂÙÂÚˆÙÈÎ ÓÙÈÂÚ ıúô ÔÈËÙÈÎ ÓÙÈÛÒÌ Ù, Ë Ô Ô Û ÂÙ ÂÙ È Ì ÙË ıâú  Ì Aranesp Î Ú ˆ Û ÛıÂÓ Ì ÃÚfiÓÈ ÂÊÚÈÎ Ó ÚÎÂÈ (à ) Ô Ï Ì ÓÔ Ó ÙË ıâú Â Ô ÔÚ ˆ. ÙËÓ ÂÚ ÙˆÛË Ô È ÁÓˆÛı PRCA Ë ıâú  Ì Aranesp Ú ÂÈ Ó È Îfi ÙÂÙ È Î È ÔÈ ÛıÂÓ ÂÓ ı Ú ÂÈ Ó ÌÂÙ Ù ÛÛÔÓÙ È Û ÏÏË Ó Û Ó È ÛÌ ÓË ÂÚ ıúô ÔÈËÙÈÎ Úˆ- Ù ÓË ( Ï. Ú ÁÚ ÊÔ 4.4). ñ ÏÏÂÚÁÈÎ ÓÙÈ Ú ÛÂÈ, Û Ì ÂÚÈÏ Ì ÓÔÌ ÓˆÓ Ó Ê Ï ÎÙÈÎ ÓÙ Ú ÛË, ÁÁÂÈÔÔÈ Ì ÙÔ, ÂÚÌ ÙÈÎÔ ÂÍ Óı Ì ÙÔ Î È ÎÓ ˆÛË. ñ ÛÌÔ. 4.9 À ÂÚ ÔÛÔÏÔÁ : Ô ıâú  ÙÈÎfi ÂÚÈıÒÚÈÔ ÙÔ Aranesp Â Ó È ÔÏ Â Ú. ÎfiÌ Î È Û ÔÏ ËÏ Â Â ÔÚÔ, ÂÓ Ô Ó Ú ÙËÚËıÂ Û Ì ÙÒÌ Ù ÂÚÔ ÔÛÔÏÔÁ.  ÂÚ ÙˆÛË ÂÌÊ ÓÈÛË ÔÏ Î ÙÙ Ú ÈÌ, Ë ÔÚ ÁËÛË ÙÔ Aranesp ı Ú - ÂÈ Ó Ó ÛÙ ÏÏÂÙ È ÚÔÛˆÚÈÓ ( Ï. Ú ÁÚ ÊÔ 4.2). Ó ÂÓ Â ÎÓ Ù È ÎÏÈÓÈÎ, ÂÓ ÂÙ È Ó ÈÂÓÂÚÁËı ÊÏÂ- ÔÙÔÌ. 7. à π À º ƒπ : Amgen Europe B.V., Minervum 7061, NL-4817 ZK Breda, ÏÏ Ó. 8. ƒπ ª ( π) π À º ƒπ : EU/1/01/185/ , EU/1/01/185/ , EU/1/01/185/ , EU/1/01/185/ , EU/1/01/185/ ª ƒ ª π ƒø π / ø π : ÌÂÚÔÌËÓ ÚÒÙË ÂÈ : 8 πô Ó Ô 200 ÌÂÚÔÌËÓ ÙÂÏÂ Ù Ó Ó ˆÛË : 19 M Ô ª ƒ ª π øƒ À πª À: 28 ÎÙˆ Ú Ô Â ÙÔÌÂÚ ÏËÚÔÊÔÚÈ Î ÛÙÔÈ Â ÁÈ ÙÔ ÚfiÓ ÚÔ fió Â Ó È È ı ÛÈÌ ÛÙËÓ ÈÛÙÔÛÂÏ ÙÔ Úˆ ÎÔ ÚÁ ÓÈÛÌÔ º ÚÌ ÎˆÓ (EMEA) È Ï ÚÂÈ Û ÓÙ ÁÔÁÚ ÊÈÎ ÏËÚÔÊÔÚ Â Ú Î ÏÔ Ì  ÈÎÔÈÓˆÓ ÛÙ Ì ÙËÓ ÓÂÛÈ º ÚÌ..

9 committees International Advisory Committee, National Representatives Chairman Greece Pentheroudakis George, Medical Oncologist Members Albania Algeria Bosnia and Herzegovina Croatia Cyprus Egypt France Greece Israel Italy Lebanon Libya Malta Monaco Montenegro Morocco Spain Slovenia Syria Tunisia Turkey Sallaku Agim, Medical Oncologist Boubrit Mustapha, Oncology Surgeon Beslija Semir, Medical Oncologist Plestina v Stjepko, Medical Oncologist Adamou Adamos, Medical Oncologist Gaafar Rabab, Medical Oncologist Lamarque Jean-Louis, Oncology Surgeon Samonis George, Medical Oncologist Sulkes Aaron, Medical Oncologist Testori Alessandro, Medical Oncologist Geahchan Negib, Oncology Surgeon El Mistiri Mufid, Medical Oncologist Metaraku Donika, Medical Oncologist Mourou Michel Yves, Oncology Surgeon Todorovic Vladimir, Medical Oncologist Chafik Chraibi, Oncology Gynaecologist Tabernero Josep, Medical Oncologist Matos Erika, Medical Oncologist Jadid Hasan, Oncology Surgeon Radhi Hamza, Medical Oncologist Suayib Yalcin, Medical Oncologist 7 MMOF

10 faculty Adamou Adamos Androulakis George Aravantinos Gerasimos Arber Nadir Asimakopoulos Georgios Askoxilakis Ioannis Atay Sevcan Athanasiades Helias Aysin Kayis Bafaloukos Dimitrios Balaska Georgia Bamias Aristotle Bavbek Sevil Beqiri Arben Berkarda Bulent Besse Benzamin Boleti Ekaterini Bouzid Tarek Briasoulis Evangelos Casali Paolo G. Chabannon Christian Charalambous Andreas Chraibi Chafik Christodoulou Christos Christopoulou Athena Crino Lucio Demir Gokhan Demirkazik Ahmet Douzinas Makis Di Nicolantonio Federica Dubois Jean-Bernard Efremidis Anna Elad Sharon Ellis Paul Emmanouilides Christos Fernadez-Ortega Paz Ficarra Vincenzo Franceschi Silvia Fumoleau Pierre Gaafar Rabab Garassino Marina Georgiadis Konstantinos Gogas Helen Gundogdu Fatma Ignatiadis Michail Medical Oncologist, Cyprus Surgeon, Greece Medical Oncologist, Israel Breast Surgeon, Greece Breast Surgeon, Greece Oncology Nurse, Turkey Oncology Nurse, Turkey Psychologist, Greece Medical Oncologist, Turkey Oncology Surgeon, Albania Medical Oncologist, Turkey Medical Oncologist, France Medical Oncologist, UK Medical Oncologist, Tunisia Medical Oncologist, Italy Cell Biologist, France Oncology Nurse, Cyprus Gynaecologist, Maroco Medical Oncologist, Italy Medical Oncologist, Turkey Medical Oncologist, Turkey Thoracic Surgeon, Greece Molecular Biologist, Italy Radiation Oncologist, France Dentist-Oral Oncology, Israel Medical Oncologist, UK Oncology Nurse, Spain Urologist, Italy Medical Oncologist, France Medical Oncologist, France Medical Oncologist, Egypt Medical Oncologist, Italy Technician-Radiologist, Greece Oncology Nurse, Turkey Medical Oncologist, Belgium MMOF 8

11 faculty Jezdic Svetlana Kakolyris Stylianos Kalofonos Charalambos Karagianni Aikaterini Karamouzis Michalis Kardamakis Dimitrios Karlou Chrysoula Katsaragakis Stylianos Kav Sultan Kaynak Kamil Klein Baruch Kosmidis Paris Kottaridis Panos Lemonidou Chrysoula Linardou Helena Loupakis Fotios Piulats Jose M. Maniadakis Nikos Marinos Nikos Mayordomo Jose Ignacio Michailidis Michail Milani Alessandra Molinas Mandel Nil Mountzios Ioannis Murray Samuel Navrozoglou Iordanis Nicolatou Galitis Ourania Onat Haluk Papadimitriou Christos Papadouri Anna Papageorgiou Dimitrios Papakostas Pavlos Papamichael Dimitrios Papandreou Christos Pappa Theodora Patiraki Elisavet Pectasides Dimitrios Pentheroudakis George Petridou Eleni Peterson Douglas Plestina v Stjepko Medical Oncologist, Switzerland Dentist-Oral Oncology, Greece Radiation Oncologist, Greece Oncology Nurse, Greece Oncology Nurse, Greece Oncology Nurse, Turkey Thoracic Surgeon, Turkey Medical Oncologist, Israel Haematologist, UK Oncology Nurse, Greece Medical Oncologist, Italy Medical Oncologist, Spain Economist, Greece Radiation Oncologist, Greece Medical Oncologist, Spain Technician-Radiologist, Greece Oncology Nurse, Italy Medical Oncologist, Turkey Molecular Biologist, Greece Gynaecologist, Greece Dentist-Oral Oncology, Greece Medical Oncologist, Turkey Oncology Nurse, Greece Oncology Nurse, Greece Medical Oncologist, Cyprus Oncology Nurse, Greece Oncology Nurse, Greece Epidemiologist, Greece Dentist-Oral Oncology, USA Medical Oncologist, Croatia 9 MMOF

12 faculty Porta Camillo Poulakaki Fiorita Psirri Amanta Psychogiou Argyro Razis Evagelia Retsas Spyros Rosti Giovanni Roussakis Sotirios Saip Pinar Samantas Epameinondas Samonis George Shamaa Sameh Skarlos Dimosthenis Sotiriou Christos Syrigos Konstantinos Tarampikou Anthi Testori Alessandro Thanos Dimitrios Tortora Giampaolo Tountas Ioannis Trichopoulou Antonia Tsakiris Georgios Tsekeris Pericles Tsiftsis Dimitrios Tsiotos Grigorios Veronesi Paolo Viale Giuseppe Viteri Santiago Vlastos George Vogel Victor Xepapadakis Grigorios Yaffe Aliza Yalcin Suayib Yarden Yosef Yucel Idris Zervoudis Stefanos Zielinski Christoph Zografos George Medical Oncologist, Italy Breast Surgeon, Greece Oncology Nurse, Greece Medical Oncologist, UK Medical Oncologist, Italy Oncology Nurse, Greece Medical Oncologist, Turkey Medical Oncologist, Egypt Medical Oncologist, Belgium Oncology Nurse, Greece Medical Oncologist, Italy Molecular Biologist, Greece Medical Oncologist, Italy Epidemiologist, Greece Biopathologist, Nutritionist, Greece Radiation Oncologist, Greece Radiation Oncologist, Greece Surgeon, Greece Surgeon, Greece Surgeon, Italy Pathologist, Italy Medical Oncologist, Spain Breast Surgeon, Switzerland Medical Oncologist, USA Breast Surgeon, Greece Oncology Nurse, Israel Medical Oncologist, Turkey Molecular Biologist, Israel Medical Oncologist, Turkey Breast Surgeon, Greece Medical Oncologist, Austria Breast Surgeon, Greece MMOF 10

13 SCIENTIFIC PROGRAMME 11

14

15 scientific programme Thursday, September 10, Registration Welcome and introduction Symposium: Multidisciplinary Approaches in Genitourinary Cancer Prostate Cancer Chairpersons: Ch. Papadimitriou (Greece), M.N. Molinas (Turkey) Novel approaches in the management of localized tumours: what and for whom? V. Ficarra (Italy) Hormone refractory prostate cancer: when to treat and how? J. M. Piulats (Spain) Novel targets and agents C. Papandreou (Greece) Renal Cancer Chairpersons: S. Retsas (UK), Ch. Emmanouilides (Greece) Case 1: when is nephrectomy indicated? S. Bavbek (Turkey) Case 2: first line standard of care E. Boleti (UK) Treatment algorithm based on recent advances & Concluding remarks A. Bamias (Greece) C o f f e e b r e a k Proffered papers (Session I) Translational Research Chairpersons: E. Samantas (Greece) C. Chraibi (Morocco) O 0 COMBINED TREATMENT WITH ANTIANGIOGENETIC AND ANTI-EGFR AGENTS IN GLIOBLASTOMA Giannopoulou E. 1, Dimitropoulos K. 1, Argyriou A. 1, Kalofonos Ch. 1 Clinical Oncology Laboratory, Division of Oncology, Department of Medicine, University Hospital of Patras, Patras Medical School, Rio, Greece O 02. The RelatIonshIp Between AntImetabolIte ToxIcIty and PharmacogenetIcs Dogan M. 1, Gurhan Karabulut H. 2, Tukun A. 2, Demirkazik A. 1, Ozal G. 1, Utkan G. 1, Yalcin B. 1, Dincol D. 1, Akbulut H. 1, Icli F. 1 Ankara University School of Medicine, Department of Medical Oncology, Ankara, Turkey, 2. Ankara University School of Medicine, Department of Medical Genetics, Ankara, Turkey O 03. Serum Vascular Endothelial Growth Factor in Non-Small Cell Lung Cancer Yahia M. 1, Gaafar R. 1, Mansour O. 1, Elgamal B. 2, Aly Eldin N. 3 Department of Medical Oncology, National cancer Institute, Cairo University, Cairo, Egypt, 2. Department of Clinical Pathology, National cancer Institute, Cairo University, Cairo, Egypt, 3. Department of Epidemiology and Statistics, National cancer Institute, Cairo University, Cairo, Egypt O 04. The Effect of HER2 Expression On Cisplatin-Based Chemotherapy In Advanced Non- Small Cell Lung Cancer Patients Calikusu Z. 1, Yildirim Y. 2, Akcali Z. 3, Sakalli H. 3, Bal N. 4, Unal I. 5, Ozyilkan O. 3 Department of Medical Oncology, Acibadem Hospital, Istanbul, Turkey, 2. Department of Medical Oncology, Sivas Numune Hospital, Sivas, Turkey, 3. Department of Medical Oncology, Baskent University Faculty of Medicine, Ankara, Turkey, 4. Department of Pathology, Baskent University Faculty of Medicine, Ankara, Turkey, 5. Department of Biostatistics, Cukurova University Faculty of Medicine, Adana, Turkey O 05. INCREASED EXPRESSION OF NFY-C (NUCLEAR FACTOR Y, SUBUNIT C) AND RORA (RETINOIC ACID RECEPTOR- RELATED ORPHAN RECEPTOR ALPHA) IN COLORECTAL ADENOCARCINOMA. Kottorou A. 1, Antonacopoulou A. 1, Giannopoulou E. 1, Grivas P. 1, Scopa C. 2, Kalofonos Ch. 1 Division of Oncology and Clinical Oncology Laboratory, Department of Internal Medicine, Medical School, University of Patras, Rio, Greece, 2. Department of Pathology, Medical School, University of Patras, Rio, Greece 13 MMOF

16 Thursday, September 10, 2009 scientific programme O 06. WNT-1 EXPRESSION IS RELATED WITH LESS AGGRESSIVE PHENOTYPE IN PATIENTS WITH INVASIVE BREAST CARCINOMAS Korakaki A. 1, Giannopoulou I. 1, Vamvakaris I. 1, Magkou C. 1, Theohari I. 1, Papadimitriou C. 1, Keramopoulos A. 1, Dimopoulos A. 1, Nakopoulou L. 1 1st Department of Pathology and Department of Clinical Therapeutic, Medical School, University of Athens, Greece O 07. IdentIfIcatIon of patients who may benefit from the prophylactic cranial radiotherapy among breast cancer patients with brain metastasis. Saip P. 1, Cicin I. 1, Eralp Y. 1, Karagol H. 1, Kucucuk S. 1, Cosar Alas R. 1, Yavuz E. 1, Dincer M. 1, Saglam E. 1, Topuz E. 1 Department of Medical Oncology, Institute of Oncology, Istanbul University, Turkey. O 08. INTRAVENOUS (IV) IRON SUPPLEMENTATION IN CONJUCTION WITH ERYTHROPOIESIS STIMULATING AGENTS (ESAS) IN CHEMOTHERAPY-INDUCED ANEMIA: META-ANALYSIS OF DATA FROM RANDOMIZED TRIALS Rosti G. 1, Secondino S. 2, Giordano L. 2, Garassino I. 2, Gandini C. 2, Santoro A. 2, Pedrazzoli P. 2 Medical Oncology Treviso, Italy, 2. Humanitas Institute Rozzano, Italy O 09. Somatic mutations in KRAS: mechanism of resistance to anti-egfr therapies. Systematic review and meta-analysis of studies in metastatic colorectal cancer Kanaloupiti D. 1, Linardou H. 1, Dahabreh IJ. 2, Siannis F. 3, Bafaloukos D. 1, Kosmidis P. 4, Papadimitriou Ch. 5, Murray S. 6 Α Department of Oncology, Metropolitan Hospital, Athens, Greece, 2. Medical School, Athens University, Greece, 3. Department of Mathematics, Athens University and MRC Biostatistics Unit, Cambridge, UK, 4. Β Department of Oncology, Hygeia Hospital, Athens, Greece, 5. University Oncology Clinic, Alexandras Hospital, Athens, Greece, 6. Department of Molecular Biology & Genetics, Metropolitan Hospital, Athens, Greece O 10. DESCRIBING THE EFFECTS OF CANCER TREATMENTS: PROGRESSION-FREE-SURVIVAL (PFS) IS MORE RELIABLE THAN TIME-TO-PROGRESSION (TTP) Porzsolt F. 1, Weber A. 1, Zajicek G. 2, Muche R. 3 Clinical Economics, University of Ulm, Germany, 2. Developmental Biology and Cancer Research, Faculty of Medicine, Hebrew University of Jerusalem, Israel, 3. Dept. Biostatistics and Medical Information, University of Ulm, Germany L u n c h b r e a k Proffered papers (Session II) Nursing and Supportive Care Chairpersons: P. Papakostas (Greece), S. Roussakis (Greece) O 1 TREATMENT AND PREVENTION OF BISPHOSHONATE-ASSOCIATED OSTEONECROSIS OF THE JAWS Papadopoulou E. 1, Nicolatou-Galitis O. 1, Karayianni A. 2, Kirtsoni C. 3, Repousis P. 4, Kokkini G. 5, Barbounis V. 6, Samadas E. 7 Clinic of Hospital Dentistry, Dental Oncology Unit, School of Dentistry, University of Athens, Greece, 2. Clinic of Oral Diagnosis and Radiology, School of Dentistry, University of Athens, Greece, 3. Hospital «LAIKO», Hematological Clinic, Medical School, University of Athens, Greece, 4. Anticancer Hospital «METAXA», Hematological Clinic, Piraeus, Greece, 5. Hospital «SISMANOGLEIO», Hematological Clinic, Athens, Greece, 6. Anticancer Hospital «Saint Savvas», Athens, Greece, 7. Hospital «AGIOI ANARGYROI», Athens, Greece O 12. ΟRAL MUCOSITIS, PAIN AND XEROSTOMIA IN PATIENTS WITH HEAD AND NECK CANCER WHO RECEIVED CHEMORADIOTHERAPY WITH OR WITHOUT CETUXIMAB. A COMPARATIVE CLINICAL STUDY Sarri T. 1, Nicolatou-Galitis O. 1, Polychronopoulou A. 2, Koukoulias V. 3, Dardoufas K. 4, Vakalis K. 5, Demenagas D. 6, Sotiropoulou-Lontou A. 6 Clinic of Hospital Dentistry, Dental School, University of Athens, Greece, 2. Department of Preventive and Community Dentistry, School of Dentistry, University of Athens, Greece, 3. Department of Radiotherapy, «Attikon» Hospital, School of Medicine, University of Athens, Greece, 4. Department of Radiotherapy, «Ygeia» Hospital, Athens, Greece, 5. Department of Radiotherapy, «401 Hospital», Athens, Greece, 6. 2nd Radiotherapy Dpt, Saint Savvas Hospital, Athens, Greece MMOF 14

17 scientific programme Thursday, September 10, O 13. Educational Program for Nurses on Prevention and Management of Cancer Treatment induced Oral Mucositis Kav S. 1, Borulday B. 1, Sergi C. 1, Goktan N. 1, Melek S. 1, Karaman Nu. 2 Baskent University Faculty of Health Sciences, Department of Nursing, Ankara, Turkey, 2. Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, Ankara, Turkey O 14. XEROSTOMIA IN CANCER THERAPY: AETIOLOGY, ORAL/DENTAL SEQUELAE, TREATMENT AND PREVENTION Nicolatou-Galitis O. 1, Sotiropoulou-Lontou A. 2, Kouloulias V. 3, Dardoufas K. 4, Vakalis X. 5, Kyprianou K. 5, Georgakopoulos G. 6, Pissakas G. 7, Kolitsi G. 8, Kouvaris J. 4 School of Dentistry, Dental Oncology Unit, Greece, 2. Saint Savvas Hospital, 2nd Radiotherapy Dpt, Athens, Greece, 3. Attikon Hospital, Radiotherapy Dpt, Athens, Greece, 4. Aretaieion Hospital, Radiotherapy Dpt, Athens, Greece, 5. Euromedica, Radiotherapy Dpt, Athens, Greece, 6. 1st IKA, Radiotherapy Dpt, Athens, Greece, 7. Alexandras Hospital, Radiotherapy Dpt, Athens, Greece, 8. Hygeia Hospital, Radiotherapy Dpt., Athens Greece O 15. EFFICACY AND TOLERABILITY OF PALONOSETRON IN COMBINATION WITH APREPITANT AND DEXAMETHASONE IN PATIENTS RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY Okutur K. 1, Aydin K. 1, Bozkurt M. 1, Demir N. 2, Turan C. 2, Demir G. 1 Istanbul Bilim University, School of Medicine, Medical Oncology Department, Istanbul, Turkey, 2. Istanbul Bilim University, School of Medicine, Internal Medicine Department, Istanbul, Turkey O 16. NEEDS OF GASTROINTESTINAL CANCER PATIENTS DURING AND AFTER TREATMENT IN GREECE Heras P., Hatzopoulos A., Hera M., Xourafas V., Mantzioros M., Kritikos K. Hellenic Medical Society for the Study of Psychosomatic Problems, Greece O 17. PSYCHOMETRIC EVALUATION OF THE GREEK PITTSBURGH SLEEP QUALITY INDEX (GR-PSQI) IN CANCER PATIENTS RECEIVING ACTIVE-PHASE TREATMENT Kotronoulas G. 1, Papadopoulou C. 2, Papapetrou A. 3, Patiraki E. 4 University of Stirling, Scotland, UK, 2. «Attikon» University Hospital, University of Stirling, Scotland, UK, 3. «Hygeia» Hospital, Athens, Greece, 4. University of Athens, Greece O 18. IDENTIFYING SYMPTOM CLUSTERS IN PAEDIATRIC CANCER PATIENTS USING THE MEMORIAL SYMPTOM ASSESSMENT SCALE Atay S. 1, Conk Z. 2, Bahar Z. 3 Hacettepe University, Ankara, Turkey, 2. Ege University, Izmir, Turkey, 3. Dokuz Eylul University, Izmir, Turkey O 19. Female breast cancer patients body image assessment Psychogyiou Α. 1, Giannakopoulou M. 2, Katsaragakis S. 2, Patiraki E. 2 St Savas Cancer Hospital, Athens, Greece, 2. Nursing Faculty, National and Kapodistrian University of Athens, Greece O 20. SELF-EFFICACY BELIEFS AND LEVELS OF ANXIETY IN ADVANCED CANCER PATIENTS Parpa E. 1, Mystakidou K. 1, Tsilika E. 1, Gogou P. 2, Theodorakis P. 3, Vlahos L. 2 Pain Relief and Palliative Care Unit, Areteion Hospital, Radiology Department, School of Medicine, University of Athens, Greece, 2. Areteion Hospital, Radiology Department, School of Medicine, University of Athens, Greece, 3. Health & Social Solidarity, Municipality of Athens, Greece 15 MMOF

18 Thursday, September 10, 2009 scientific programme Symposium: Cancer Prevention: reality or dream? Chairpersons: E. Petridou (Greece), B. Berkarda (Turkey) Epidemiology and cancer prevention across the Mediterranean : differences and similarities S. Franceschi (France) Implementation of population screening programs: the challenge and the role of local governments N. Arber (Israel) Chemoprevention: where do we stand today? (breast, prostate Ca, colorectal) V. Vogel (USA) Mediterranean diet and cancer A. Trichopoulou (Greece) Discussion Keynote Lecture Chairpersons: S. Murray (Greece), M. Garassino (Italy) Molecular Oncology the era of individualised cancer management? Y. Yarden (Israel) Depart for the Opening Ceremony to be held at the Acropolis Museum Opening Ceremony Chairpersons: D. Bafaloukos (Greece), A. Testori (Italy) Welcome Addresses Guided visit to the Acropolis Museum Welcome Reception at the Veranda of the Acropolis Museum Restaurant MMOF 16

19 scientific programme Τhursday, September 10, Oncology Nursing Symposium Symptom Management in Oncology Patients: Nursing Perspectives Chairpersons: E. Patiraki (Greece) S. Kav (Turkey) Welcome and Introduction A. Tarampikou (Greece) Introduction Lecture Chairperson: E. Patiraki (Greece) Symptom management as a high research priority in oncology nursing S. Kav (Turkey) Round Table Nursing Management of Patients with Difficult Physical Symptoms Chairpersons: Ch. Lemonidou (Greece), D. Papageorgiou (Greece) Fatigue A. Yaffe (Israel) Pain P. Fernandez-Ortega (Spain) Breathlessness S. Katsaragakis (Greece) Nausea Vomiting A. Charalambous (Cyprus) Alopecia A. Milani (Italy) Discussion C o f f e e b r e a k Lecture Chairperson : A. Psychogiou (Greece) Symptoms Psychological Effects : How to Help Patients Develop Coping Strategies G. Balaska (Greece) Lecture Chairperson: A. Papadouri (Greece) Symptom Cluster: The New Frontier in Symptom Management S. Atay (Turkey) Discussion Forum. Relieving Physical and Emotional Burden of Cancer Patients: Mediterranean Countries Reality and Vision Chairpersons: D. Pappa (Greece), F. Gundogdu (Turkey) Cyprus: A. Charalambous Greece: Ch. Karlou Israel: A. Yaffe Italy: A. Milani Spain: P. Fernandez-Ortega Turkey: K. Aysin I I L u n c h b r e a k I I 17 MMOF

20 Friday, September 11, 2009 scientific programme BREAST CANCER DAY (Organized by Roche Hellas) Deconstructing breast cancer Chairpersons: P. Kosmidis (Greece), G. Asimakopoulos (Greece) Breast Cancer Day 2009: Leading our expectations P. Kosmidis (Greece) Breast cancer awareness in Greece: Where do we stand today? I. Tountas (Greece) Current dilemmas in the treatment of breast cancer A. Efremidis (Greece) 10: Evolution of breast cancer therapy: The revolution of targeting agents Ch. Sotiriou (Belgium) C o f f e e b r e a k EBC session Setting the treatment perspectives in early breast cancer Chairpersons: K. Syrigos (Greece), G. Xepapadakis (Greece) 11: Pursuing accuracy of HER2 testing G. Viale (Italy) 11: Chance for cure in Early Breast Cancer P. Elis (UK) 11: Discussion 12: MBC session Prolonging survival in the treatment of metastatic breast cancer Chairpersons: D. Pectasides (Greece), S. Kakolyris (Greece) 12: Advancing the treatment landscape of HER2 positive patients P. Fumoleau (France) 12: Controlling angiogenesis - Transforming the treatment landscape of HER2 negative patients Ch. Zielinski (Austria) Discussion 13: Treating breast cancer in daily practice Chairpersons: A. Efremidis (Greece), Ch. Zielinski (Austria) 13: Early breast cancer in daily practice (case study) H. Gogas (Greece) 13: HER2 positive metastatic breast cancer in daily practice (case study) E. Razis (Greece) 13: HER2 negative metastatic breast cancer in daily practice (case study) I. Yϋcel (Turkey) 13: Discussion 14: Reconstructing breast cancer: Take home messages in 2009 and beyond A. Efremidis (Greece) 14:30-16:00 L u n c h B r e a k 15:00-16:00 Poster Discussion Session Chairpersons: S. Zervoudis (Greece), I. Navrozoglou (Greece), C. Christodoulou (Greece) MMOF 18

E Ã E I P I I O Ã P H T H BEST III 56K PCI BEST MODEM SERIES

E à E I P I I O à P H T H BEST III 56K PCI BEST MODEM SERIES E à E I P I I O à P H T H BEST III 56K PCI BEST MODEM SERIES 1. Eƒπ à ª À À π BEST II PCI MODEM H Û ÛÎÂ Û ÙÔ modem appleâúèï Ì ÓÂÈ : 1. Crypto Best III 56K PCI modem 2. ËÏÂʈÓÈÎfi Î ÏÒ ÈÔ RJ-11 3. ÔÁÈÛÌÈÎfi

More information

FINAL AND PERMANENT VERSION THURSDAY, FEBRUARY 17, 2011 DAY 1 (FRIDAY, MAY 6, 2011): Chairpersons: E. Özer (TR) - S.A.Raptis (GR)

FINAL AND PERMANENT VERSION THURSDAY, FEBRUARY 17, 2011 DAY 1 (FRIDAY, MAY 6, 2011): Chairpersons: E. Özer (TR) - S.A.Raptis (GR) FINAL AND PERMANENT VERSION THURSDAY, FEBRUARY 17, 2011 1 st TURKISH-HELLENIC POSTGRADUATE CONTINUOUS MEDICAL EDUCATION MEETING MAY 6-9, 2011, IZMIR, TURKEY DAY 1 (FRIDAY, MAY 6, 2011): Chairpersons: E.

More information

Friday 29 th, October 2010

Friday 29 th, October 2010 Friday 29 th, October 2010 15:00-17:00 Registration 17:00-18:00 Opening Ceremony 18:00-18:30 Refreshment Break 18:30-19:00 Plenary Lecture I Nazli Gad El Mawla Memorial Lecture Chairpersons: Prof. Dr.

More information

30-31. Advancesincancer immunologyand immunotherapy. announcement. October2015. Royal Olympic Hotel Athens

30-31. Advancesincancer immunologyand immunotherapy. announcement. October2015. Royal Olympic Hotel Athens Advancesincancer immunologyand immunotherapy 30-31 October2015 Royal Olympic Hotel Athens announcement Organizer Hellenic Oncology Research Group (HORG) Symposium chairs N. Kentepozidis, A. Kotsakis, M.

More information

Δ Δ Δ À 19Ô πø. ATHENS AT THE END OF THE 19th CENTURY

Δ Δ Δ À 19Ô πø. ATHENS AT THE END OF THE 19th CENTURY Δ Δ Δ À 19Ô πø ATHENS AT THE END OF THE 19th CENTURY ÓÙ apple ÓÔÚ ÌÈÎ applefi ÂÈ ÙË ı Ó Ï ÁÔ appleúèó applefi ÙËÓ Â ÛÔ Ô ÙÔ 20Ô ÈÒÓ. apple ÙÈ ÌËÏ fiúôê Î È ÙÚÈfiÚÔÊ, ÎÂÚ ÌÔÛÎÂapple appleôïèùâ appleïˆì

More information

June 27, 2015 Radisson Blu Hotel Sisli - Istanbul

June 27, 2015 Radisson Blu Hotel Sisli - Istanbul 5 June 27, 2015 Radisson Blu Hotel Sisli - Istanbul INVITATION On behalf of the Turkish Medical Oncology Society Executive Committee, it th is my pleasure to invite you to join the 6 ASCO-licensed "Best

More information

Avastin in breast cancer: Summary of clinical data

Avastin in breast cancer: Summary of clinical data Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading

More information

GRANT APPLICATION FORM: ORGANISING AN ESO EDUCATIONAL EVENT

GRANT APPLICATION FORM: ORGANISING AN ESO EDUCATIONAL EVENT GRANT APPLICATION FORM: ORGANISING AN ESO EDUCATIONAL EVENT 1) TOPIC OF THE EVENT MALIGNANT PLEURAL DISEASE 2) SUGGESTED TITLE : Approach to Pleural Cancer: State-of-the-Art 3) TYPE OF EVENT Course Native

More information

MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS

MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS All prescriptions for antineoplastic drugs must be accompanied by the MOH special form. All the attachments mentioned on this form shall be submitted

More information

The Cancer Patient Journey. Dr. Jaco Fourie

The Cancer Patient Journey. Dr. Jaco Fourie The Cancer Patient Journey Dr. Jaco Fourie The Cancer Patient Journey Prevention and health promotion Screening Diagnosis and staging Treatment Surveillance and survivorship End of life care The Cancer

More information

Avastin: Glossary of key terms

Avastin: Glossary of key terms Avastin: Glossary of key terms Adenocarcinoma Adenoma Adjuvant therapy Angiogenesis Anti-angiogenics Antibody Antigen Avastin (bevacizumab) Benign A form of carcinoma that originates in glandular tissue.

More information

Avastin in breast cancer: Summary of clinical data

Avastin in breast cancer: Summary of clinical data Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading

More information

The following information is only meant for people who have been diagnosed with advanced non-small cell

The following information is only meant for people who have been diagnosed with advanced non-small cell Important information for people with advanced non-small cell lung cancer The following information is only meant for people who have been diagnosed with advanced non-small cell lung cancer (NSCLC). NSCLC

More information

New strategies in anticancer therapy

New strategies in anticancer therapy 癌 症 診 療 指 引 簡 介 及 臨 床 應 用 New strategies in anticancer therapy 中 山 醫 學 大 學 附 設 醫 院 腫 瘤 內 科 蔡 明 宏 醫 師 2014/3/29 Anti-Cancer Therapy Surgical Treatment Radiotherapy Chemotherapy Target Therapy Supportive

More information

Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012. (minutes for web publishing)

Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012. (minutes for web publishing) Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology

More information

SMALL CELL LUNG CANCER

SMALL CELL LUNG CANCER Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New

More information

Cancer treatment. TOP EUROPEAN CANCER EXPERTISE The path to recovery

Cancer treatment. TOP EUROPEAN CANCER EXPERTISE The path to recovery Cancer treatment TOP EUROPEAN CANCER EXPERTISE The path to recovery 0% LAND OF HIGH QUALITY HEALTHCARE Located in Finland, a land of high quality healthcare, Helsinki University Hospital is regarded as

More information

What is New in Oncology. Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals

What is New in Oncology. Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals What is New in Oncology Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals Personalized Medicine Personalized Genomics Genomic Medicine Precision Medicine Definition Application

More information

1 page Overview. CONCURRENT 1D, 1E, 1F Biology & Pathogenesis Multi-Modality Immunology 1

1 page Overview. CONCURRENT 1D, 1E, 1F Biology & Pathogenesis Multi-Modality Immunology 1 1 page Overview 21 Oct Tuesday 1500 on REGISTRATION 1800 Welcome Reception & Cocktails at the Cape Town International Conference Centre (CTICC) 22 Oct Wednesday 0730 REGISTRATION 0830 OPENING 0900 PLENARY

More information

REPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM

REPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM REPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM Valerie Van Damme, Isabelle Wauters, Johan Vansteenkiste Univ. Hospital Leuven and Leuven Lung Cancer Group Introduction Perspectives in Lung Cancer (PILC)

More information

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT

More information

Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer

Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line

More information

Report series: General cancer information

Report series: General cancer information Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for

More information

The Brain and Spine CenTer

The Brain and Spine CenTer The Br ain and Spine Center Choosing the right treatment partner is important for patients facing tumors involving the brain, spine or skull base. The Brain and Spine Center at The University of Texas

More information

Primary Care Management of Colorectal Cancer

Primary Care Management of Colorectal Cancer Primary Care Management of Colorectal Cancer Dr. Dan Renouf, Medical Oncologist, BC Cancer Agency Vancouver Centre November 1, 2014 www.fpon.ca Primary Care Management of Colorectal Cancer Survivors Daniel

More information

British Thoracic Oncology Group (BTOG) Annual Report - April 2014 to March 2015

British Thoracic Oncology Group (BTOG) Annual Report - April 2014 to March 2015 0116 250 2811 dawn.mckinley@uhl-tr.nhs.uk www.btog.org @BTOGORG British Thoracic Oncology Group (BTOG) Annual Report - April 2014 to March 2015 BTOG s Aim BTOG is the multi-disciplinary group for professionals

More information

2 nd ESSO Advanced Course on the Surgical and Medical Management of Melanoma

2 nd ESSO Advanced Course on the Surgical and Medical Management of Melanoma 2 nd ESSO Advanced Course on the Surgical and Medical Management of Melanoma Focus on stage III and IV melanoma In partnership with the Society of Surgical Oncology (SSO) 12-14 November 2015 ATHENS (GR)

More information

Targeted Therapy What the Surgeon Needs to Know

Targeted Therapy What the Surgeon Needs to Know Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures

More information

Lung Cancer: More than meets the eye

Lung Cancer: More than meets the eye Lung Cancer Education Program November 23, 2013 Lung Cancer: More than meets the eye Shantanu Banerji MD, FRCPC Presenter Disclosure Faculty: Shantanu Banerji Relationships with commercial interests: Grants/Research

More information

Cancer patients waiting for potentially live-saving treatments in UK

Cancer patients waiting for potentially live-saving treatments in UK Cancer patients waiting for potentially live-saving treatments in UK 29 May 2005 UK patients are waiting too long for new treatments, according to a 'Dossier of Delay' compiled by information charity CancerBACUP.

More information

CHAPTER 2. Neoplasms (C00-D49) March 2014. 2014 MVP Health Care, Inc.

CHAPTER 2. Neoplasms (C00-D49) March 2014. 2014 MVP Health Care, Inc. Neoplasms (C00-D49) March 2014 2014 MVP Health Care, Inc. CHAPTER SPECIFIC CATEGORY CODE BLOCKS C00-C14 Malignant neoplasms of lip, oral cavity and pharynx C15-C26 Malignant neoplasms of digestive organs

More information

Goals and Objectives: Breast Cancer Service Department of Radiation Oncology

Goals and Objectives: Breast Cancer Service Department of Radiation Oncology Goals and Objectives: Breast Cancer Service Department of Radiation Oncology The breast cancer service provides training in the diagnosis, management, treatment, and follow-up of breast malignancies, including

More information

2nd International Symposium on Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)

2nd International Symposium on Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) 2nd International Symposium on Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) Wednesday Oct 7th, 2015 Congress Center (Hörsaal 1 3) Marien Hospital Herne Accreditation by the Medical Chamber

More information

Future Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center

Future Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Future Directions in Clinical Research Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Outline 1. Status of Cancer Treatment 2. Overview of Clinical Research at UCDCC 3.

More information

Cetuximab (Erbitux) MM.04.005 05/10/2005. HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s) of Service: Office: Outpatient

Cetuximab (Erbitux) MM.04.005 05/10/2005. HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s) of Service: Office: Outpatient Cetuximab (Erbitux) Policy Number: Original Effective Date: MM.04.005 05/10/2005 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s)

More information

Treating Patients with Hormone Receptor Positive, HER2 Positive Operable or Locally Advanced Breast Cancer

Treating Patients with Hormone Receptor Positive, HER2 Positive Operable or Locally Advanced Breast Cancer Breast Studies Adjuvant therapy after surgery Her 2 positive Breast Cancer B 52 Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients with Hormone

More information

Surgery. Wedge resection only part of the lung, not. not a lobe, is removed. Cancer Council NSW

Surgery. Wedge resection only part of the lung, not. not a lobe, is removed. Cancer Council NSW The treatment you receive will depend on your lung cancer type, for example, whether you have a non-small cell lung cancer Adenocarcinoma or Squamous cell carcinoma, and if this is a sub-type with a mutation.

More information

Gastric Cancer. Brochure More information from http://www.researchandmarkets.com/reports/2228929/

Gastric Cancer. Brochure More information from http://www.researchandmarkets.com/reports/2228929/ Brochure More information from http://www.researchandmarkets.com/reports/2228929/ Gastric Cancer Description: Gastric cancer (GC) is one of the most common malignancies in terms of incidence and the second

More information

Epidemiology, Staging and Treatment of Lung Cancer. Mark A. Socinski, MD

Epidemiology, Staging and Treatment of Lung Cancer. Mark A. Socinski, MD Epidemiology, Staging and Treatment of Lung Cancer Mark A. Socinski, MD Associate Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive Cancer Center University of

More information

targeted therapy a guide for the patient

targeted therapy a guide for the patient targeted therapy FOR LUNG CANCER a guide for the patient TABLE OF CONTENTS lung cancer basics... 2-3 Gene changes... 4-5 Testing... 7-8 Targeted therapy... 9-11 Drugs Targeting EGFR... 12 Drugs Targeting

More information

Small Cell Lung Cancer

Small Cell Lung Cancer Small Cell Lung Cancer Types of Lung Cancer Non-small cell carcinoma (NSCC) (87%) Adenocarcinoma (38%) Squamous cell (20%) Large cell (5%) Small cell carcinoma (13%) Small cell lung cancer is virtually

More information

National Pharmaceutical Pricing Authority 3 rd Floor, YMCA Cultural Centre 1 Jai Singh Road New Delhi 110001 File No. 23(01)2014/Div.

National Pharmaceutical Pricing Authority 3 rd Floor, YMCA Cultural Centre 1 Jai Singh Road New Delhi 110001 File No. 23(01)2014/Div. Dated 21 st November 2014 NPPA Invites Comments of Pharmaceutical Industry & Trade, Consumer Organisations, Public Health Experts and other Stakeholders on the Recommendations of Tata Memorial Centre under

More information

Emerging Drug List GEFITINIB

Emerging Drug List GEFITINIB Generic (Trade Name): Manufacturer: Gefitinib (Iressa ) formerly referred to as ZD1839 AstraZeneca NO. 52 JANUARY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence:

More information

Treatment Algorithms for the Management of Lung Cancer in NSW Guide for Clinicians

Treatment Algorithms for the Management of Lung Cancer in NSW Guide for Clinicians Treatment Algorithms for the Management of Lung Cancer in NSW Guide for Clinicians Background The Cancer Institute New South Wales Oncology Group Lung (NSWOG Lung) identified the need for the development

More information

Breast. Patient information. cancer clinical pathway

Breast. Patient information. cancer clinical pathway Breast Patient information cancer clinical pathway This leaflet was written to properly inform people following breast cancer treatment plan. It doesn t replace the dialogue with healthcare staff; it rather

More information

National Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007

National Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007 Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search.

More information

TRAINING IN SURGERY IN GREECE

TRAINING IN SURGERY IN GREECE TRAINING IN SURGERY IN GREECE George N Zografos Consultant Surgeon, Athens General Hospital General Secretary Hellenic Surgical Association National Delegate, UEMS Division of General Surgery STATISTICAL

More information

Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof.

Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof. Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof. Alberto Riccardi SMALL CELL LUNG CARCINOMA Summary of treatment approach * limited

More information

A Career in Pediatric Hematology-Oncology? Think About It...

A Career in Pediatric Hematology-Oncology? Think About It... A Career in Pediatric Hematology-Oncology? Think About It... What does a pediatric hematologist-oncologist do? What kind of training is necessary? Is there a future need for specialists in this area? T

More information

ELCC 2015 Industry Satellite Symposium The Treatment Roadmap for Squamous NSCLC. Thursday 16th April 2015 13:10 14:20 Room C

ELCC 2015 Industry Satellite Symposium The Treatment Roadmap for Squamous NSCLC. Thursday 16th April 2015 13:10 14:20 Room C ELCC 2015 Industry Satellite Symposium The Treatment Roadmap for Squamous NSCLC Thursday 16th April 2015 13:10 14:20 Room C 1 Contents Programme.... 2 Welcome message.... 3 Faculty biographies.... 4 Symposium

More information

Lung Cancer Research: From Prevention to Cure!

Lung Cancer Research: From Prevention to Cure! Lung Cancer Research: From Prevention to Cure! Ravi Salgia, M.D, Ph.D Associate Professor of Medicine Director, Thoracic Oncology Research Program Department of Medicine Section of Hematology/Oncology

More information

ONCOLOGY NURSING 7 TH ESO-EONS MASTERCLASS IN. 8-13 March 2014 Ermatingen (Lake Constance) Switzerland MASTERCLASS

ONCOLOGY NURSING 7 TH ESO-EONS MASTERCLASS IN. 8-13 March 2014 Ermatingen (Lake Constance) Switzerland MASTERCLASS MASTERCLASS Photo: Turm by Stephan Balkenhol - A Sculpture for Wolfsberg Photographer: Ralph Feiner, Architekturfotografie, Malans 7 TH ESO-EONS MASTERCLASS IN ONCOLOGY NURSING 8-13 March 2014 Ermatingen

More information

2012 CANCER PROGRAM ANNUAL REPORT

2012 CANCER PROGRAM ANNUAL REPORT MERCY REGIONAL CANCER CENTER 2012 CANCER PROGRAM ANNUAL REPORT Using 2011 Data Mercy Regional Cancer Center When you have cancer, you might think first of treatments chemotherapy and radiation. You want

More information

CLINICAL ONCOLOGY MASTERCLASS IN. 25-29 April 2015 São Paulo, Brazil. Chairs: Scientific Co-ordinators: ESO - LATIN-AMERICAN PROGRAMME

CLINICAL ONCOLOGY MASTERCLASS IN. 25-29 April 2015 São Paulo, Brazil. Chairs: Scientific Co-ordinators: ESO - LATIN-AMERICAN PROGRAMME ESO - LATIN-AMERICAN PROGRAMME MASTERCLASS IN CLINICAL ONCOLOGY 25-29 April 2015 São Paulo, Brazil Chairs: N. Pavlidis, GR - R.A. Stahel, CH Scientific Co-ordinators: M. Aapro, CH - F. Cardoso, PT FOREWORD

More information

Clinical Research Committee Survey on Challenges of Conducting Surgical Trials Results

Clinical Research Committee Survey on Challenges of Conducting Surgical Trials Results Clinical Research Committee Survey on Challenges of Conducting Surgical Trials Results SURVEY RESULTS Survey population = 3500 Total responses as of 24 August 2015 = 195 Response rate = 5.6% ESSO Clinical

More information

There must be an appropriate administrative structure for each residency program.

There must be an appropriate administrative structure for each residency program. Specific Standards of Accreditation for Residency Programs in Radiation Oncology 2015 VERSION 3.0 INTRODUCTION The purpose of this document is to provide program directors and surveyors with an interpretation

More information

REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group

REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group In the 2002 edition of the ASCO meeting, a total of 315 abstracts in the field of respiratory

More information

Harmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART

Harmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART Harmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART Goals Discuss treatment options for stage 4 lung cancer: New and old Discuss new developments in personalized

More information

GENERAL QUESTIONS FOR YOUR DOCTOR OR NURSE. 3. Can you refer me to a breast cancer support group or counselor?

GENERAL QUESTIONS FOR YOUR DOCTOR OR NURSE. 3. Can you refer me to a breast cancer support group or counselor? GENERAL QUESTIONS FOR YOUR DOCTOR OR NURSE 1. You can bring members of your family or a friend to talk to the doctor or nurse directly. 2. Where can I find more information about breast cancer? 3. Can

More information

A23: Oncologic Disease- Tumor Markers

A23: Oncologic Disease- Tumor Markers A23: Oncologic Disease- Tumor Markers Diagnosis Tumor Markers and Genetic Markers Use for Specific Malignancy The following information is from multiple guideline sources as recommendations for use of

More information

Cachexia and Nutrition in Advanced Cancer Patients: a Multidisciplinary Approach Chairs: M.S. Aapro, CH J. Herrstedt, DK F.

Cachexia and Nutrition in Advanced Cancer Patients: a Multidisciplinary Approach Chairs: M.S. Aapro, CH J. Herrstedt, DK F. REPORT Cachexia and Nutrition in Advanced Cancer Patients: a Multidisciplinary Approach Chairs: M.S. Aapro, CH J. Herrstedt, DK F. Strasser, CH 13-14 March 2015 Barcelona, Spain The Conference Cachexia

More information

Public-Private Partnerships in early phase clinical research: Spurring access to innovative therapeutics

Public-Private Partnerships in early phase clinical research: Spurring access to innovative therapeutics EPAAC WP8 Research Forum - 2 July, Sofitel Hotel Europe, Brussels Public-Private Partnerships in early phase clinical research: Spurring access to innovative therapeutics JY Blay, Past President EORTC

More information

Medical Oncology. Rotation Goals & Objectives for rotating residents. General Objectives THE UNIVERSITY OF BRITISH COLUMBIA

Medical Oncology. Rotation Goals & Objectives for rotating residents. General Objectives THE UNIVERSITY OF BRITISH COLUMBIA THE UNIVERSITY OF BRITISH COLUMBIA Department of Urologic Sciences Faculty of Medicine Gordon & Leslie Diamond Health Care Centre Level 6, 2775 Laurel Street Vancouver, BC, Canada V5Z 1M9 Tel: (604) 875-4301

More information

Targeted Therapies in Lung Cancer

Targeted Therapies in Lung Cancer Targeted Therapies in Lung Cancer I Edited by: Simona Carnio Thoracic Oncology Division - St Luigi Hospital Orbassano (TO) - Italy Silvia Novello Department of Oncology - University of Torino - Italy Why

More information

Foundations of Oncology Nursing Practice

Foundations of Oncology Nursing Practice Foundations of Oncology Nursing Practice Course Syllabus Course Lead:, RN, MN, BScN, CON(C) Associate Faculty:, RN, CON(C) Last updated January 27, 2011 Course Description: This online course will introduce

More information

Lung cancer is not just one disease. There are two main types of lung cancer:

Lung cancer is not just one disease. There are two main types of lung cancer: 1. What is lung cancer? 2. How common is lung cancer? 3. What are the risk factors for lung cancer? 4. What are the signs and symptoms of lung cancer? 5. How is lung cancer diagnosed? 6. What are the available

More information

CONTENTS INVITATIONS...04 SCIENTIFIC PROGRAM...06 HELLENIC FACULTY...11 TURKISH FACULTY...14 GENERAL INFORMATION...19

CONTENTS INVITATIONS...04 SCIENTIFIC PROGRAM...06 HELLENIC FACULTY...11 TURKISH FACULTY...14 GENERAL INFORMATION...19 1 2 CONTENTS INVITATIONS...04 SCIENTIFIC PROGRAM...06 HELLENIC FACULTY...11 TURKISH FACULTY...14 GENERAL INFORMATION...19 3 INVITATION Dear Colleagues, It is with great pleasure that the Hellenic Cardiological

More information

Advances in Surgical Oncology

Advances in Surgical Oncology 3-4 December 2015 Advances in Surgical Oncology 3 rd International Conference of the Medical University of Lublin 10 th anniversary of first Intraoperative Radiotherapy in Lublin 1 Scientific Chairman

More information

Radiation Therapy in the Treatment of

Radiation Therapy in the Treatment of Lung Cancer Radiation Therapy in the Treatment of Lung Cancer JMAJ 46(12): 537 541, 2003 Kazushige HAYAKAWA Professor and Chairman, Department of Radiology, Kitasato University School of Medicine Abstract:

More information

Houston Cancer Institute

Houston Cancer Institute Houston Cancer Institute A personal path to healing Memorial-West Houston Katy Northwest Houston Southeast Houston Sugar Land Convenience for Patients State of the Art Therapies and Diagnosis Real Support

More information

7. Prostate cancer in PSA relapse

7. Prostate cancer in PSA relapse 7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined

More information

Breast Health Program

Breast Health Program Breast Health Program Working together, for your health. Breast Health Program The Breast Health Program at The University of Arizona Cancer Center offers patients a personalized approach to breast cancer,

More information

Scientific Programme

Scientific Programme Scientific Programme Scientific Committee Hilary Calvert UCL Cancer Institute, London, UK Luca Gianni Ospedale San Raffaele IRCCS, Milan, Italy Ana Maria Gonzalez-Angulo Cristiana Sessa Istituto Oncologico

More information

Your Certified Professional Cancer Coach. An Integrative Answer to Cancer Exclusive Professional Program for Patients with Cancer

Your Certified Professional Cancer Coach. An Integrative Answer to Cancer Exclusive Professional Program for Patients with Cancer Your Certified Professional Cancer Coach An Integrative Answer to Cancer Exclusive Professional Program for Patients with Cancer The CPCC Patient Program Nutrition & Lifestyle Oncology A Cancer Diagnosis

More information

PROTOCOL OF THE RITA DATA QUALITY STUDY

PROTOCOL OF THE RITA DATA QUALITY STUDY PROTOCOL OF THE RITA DATA QUALITY STUDY INTRODUCTION The RITA project is aimed at estimating the burden of rare malignant tumours in Italy using the population based cancer registries (CRs) data. One of

More information

Metastatic Melanoma What You Need to Know

Metastatic Melanoma What You Need to Know ESSENTIALS Metastatic Melanoma Metastatic Melanoma What You Need to Know If you have metastatic melanoma, you may feel as though your life has been turned upside down. It s a serious disease, but patients

More information

ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)

ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in

More information

Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study

Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study Turkish Journal of Cancer Volume 34, No.1, 2004 19 Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study MUSTAFA ÖZDO AN, MUSTAFA SAMUR, HAKAN BOZCUK, ERKAN ÇOBAN,

More information

THE SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER AT JOHNS HOPKINS

THE SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER AT JOHNS HOPKINS Ushering in a new era of cancer medicine Center is ushering in a new era of cancer medicine. Progress that could not even be imagined a decade ago is now being realized in our laboratories and our clinics.

More information

I** 25 th ESMO ANNIVERSARY and 25 th ESMO CONGRESS HAMBURG, GERMANY OCTOBER Submit your abstract via

I** 25 th ESMO ANNIVERSARY and 25 th ESMO CONGRESS HAMBURG, GERMANY OCTOBER Submit your abstract via I** % Submit your abstract via www.esmo.org EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY 25 th ESMO ANNIVERSARY and 25 th ESMO CONGRESS HAMBURG, GERMANY 13-17 OCTOBER 2000 Abstracts' deadline: 20 april 2000 Become

More information

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s

More information

Inspira (Vineland/Woobury) Open Clinical Trials as of December 16, 2015

Inspira (Vineland/Woobury) Open Clinical Trials as of December 16, 2015 Inspira (Vineland/Woobury) Open Clinical Trials as of December 16, 2015 Advanced Refractory Solid Tumors or Lymphomas ECOG-ACRIN EAY131 (NCI CIRB) Targeted Therapy Directed by Genetic Testing in Treating

More information

Multidiciplinary Management of Gastrointestinal Cancers. September 5-6, 2015, Radisson Blu Hotel Sisli- Istanbul AGENDA

Multidiciplinary Management of Gastrointestinal Cancers. September 5-6, 2015, Radisson Blu Hotel Sisli- Istanbul AGENDA Multidiciplinary Management of Gastrointestinal s September 5-6, 2015, Radisson Blu Hotel Sisli- Istanbul AGENDA Saturday, 5 September 2015 08:45 Welcome and Introduction Hakan Akbulut MD. Cem Börüban

More information

GOLNIK 17/06/10 COURSE ON LUNG CANCER AND MESOTHELIOMA. 17-18 June 2010 Golnik, Slovenia. Chair: T. Cufer, SI - G.L. Ceresoli, IT

GOLNIK 17/06/10 COURSE ON LUNG CANCER AND MESOTHELIOMA. 17-18 June 2010 Golnik, Slovenia. Chair: T. Cufer, SI - G.L. Ceresoli, IT ESO ADVANCED COURSES, SEMINARS AND SYMPOSIA GOLNIK 17/06/10 COURSE ON LUNG CANCER AND MESOTHELIOMA 17-18 June 2010 Golnik, Slovenia Chair: T. Cufer, SI - G.L. Ceresoli, IT AIM OF THE COURSE The incidence

More information

Médecine de précision médecine personnalisée en Oncologie. Fabien Calvo, Directeur Recherche et Innovation, INCa, Directeur ITMO Cancer, AVIESAN

Médecine de précision médecine personnalisée en Oncologie. Fabien Calvo, Directeur Recherche et Innovation, INCa, Directeur ITMO Cancer, AVIESAN Médecine de précision médecine personnalisée en Oncologie Fabien Calvo, Directeur Recherche et Innovation, INCa, Directeur ITMO Cancer, AVIESAN Successful targeted drug development Rapid identification

More information

Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma

Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Medical Expert: Breast Rotation Specific Competencies/Objectives 1.0 Medical History

More information

We are pleased to welcome you to the IPRAS Course: Principles and techniques in Maxillofacial Trauma, Cancer & Aesthetics.

We are pleased to welcome you to the IPRAS Course: Principles and techniques in Maxillofacial Trauma, Cancer & Aesthetics. Dear colleagues, honorable guests and friends, We are pleased to welcome you to the IPRAS Course: Principles and techniques in Maxillofacial Trauma, Cancer & Aesthetics. This course is a two-day program

More information

Treatment Guide Lung Cancer Management

Treatment Guide Lung Cancer Management Treatment Guide Lung Cancer Management The Chest Cancer Center at Cleveland Clinic, which includes specialists from the Respiratory Institute, Taussig Cancer Institute and Miller Family Heart & Vascular

More information

The Center for Prostate Cancer. Personalized Treatment. Clinical Excellence.

The Center for Prostate Cancer. Personalized Treatment. Clinical Excellence. The Center for Prostate Cancer Personalized Treatment. Clinical Excellence. The Center for Prostate Cancer Leaders in Prostate Cancer Treatment and Research The Center for Prostate Cancer at the North

More information

Advances in Lung Cancer: A Multidisciplinary Approach

Advances in Lung Cancer: A Multidisciplinary Approach Advances in Lung Cancer: A Multidisciplinary Approach Saturday, April 25, 2015 127 Public Square Cleveland, Ohio Learning Objectives About the Course This one-day course will provide a topical, clinically

More information

Guideline Development The American Society of Clinical Oncology

Guideline Development The American Society of Clinical Oncology Assessing Genomic Sequencing Information for Health Care Decision Making Decision Making Once Evidence is Assessed/Graded Evaluated Guideline Development The American Society of Clinical Oncology Gary

More information

CancerStemCell Markers in Lung Cancers: Proofsof. Reservations. Lourdes Cortes-Dericks, PhD University of Hamburg Hamburg, Germany

CancerStemCell Markers in Lung Cancers: Proofsof. Reservations. Lourdes Cortes-Dericks, PhD University of Hamburg Hamburg, Germany CancerStemCell Markers in Lung Cancers: Proofsof ConceptsandSome Reservations Lourdes Cortes-Dericks, PhD University of Hamburg Hamburg, Germany Lung cancer: highest death rate and poorest patient survival

More information

Cancer Services for Adults and Children

Cancer Services for Adults and Children UCSF HEALTH Cancer Services for Adults and Children Our world-class clinical and research programs are engaged in the urgent effort to cure cancers and, where cures currently elude us, transform cancer

More information

Metastatic breast cancer with secondary tumours: advice for patients and relatives

Metastatic breast cancer with secondary tumours: advice for patients and relatives Metastatic breast cancer with secondary tumours: advice for patients and relatives Metastatic breast cancer means that cancer cells from the original cancer in the breast spreads to other parts of the

More information

Non-Small Cell Lung Cancer Therapies

Non-Small Cell Lung Cancer Therapies Non-Small Cell Lung Cancer Therapies Guest Expert: Roy, MD, PhD Assistant Professor of Therapeutic Radiology Scott, MD Assistant Professor of Medical Oncology www.wnpr.org www.yalecancercenter.org Welcome

More information

Avastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022

Avastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022 Brochure More information from http://www.researchandmarkets.com/reports/2228475/ Avastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022 Description: Avastin (Renal Cell Carcinoma) Analysis and

More information

Nuevas tecnologías basadas en biomarcadores para oncología

Nuevas tecnologías basadas en biomarcadores para oncología Nuevas tecnologías basadas en biomarcadores para oncología Simposio ASEBIO 14 de marzo 2013, PCB Jose Jimeno, MD, PhD Co-Founder / Vice Chairman Pangaea Biotech SL Barcelona, Spain PANGAEA BIOTECH BUSINESS

More information

Lung Cancer & Mesothelioma 2011-2015

Lung Cancer & Mesothelioma 2011-2015 Lung Cancer & Mesothelioma 2011-2015 Annex G Mesothelioma 1. The vision for mesothelioma services is set out in the Mesothelioma Framework issued by DH on 26 February 2007 (supported by the British Thoracic

More information